Methods for Treating Cancer Associated with RAS Mutations

A compound targeting BRD4 and EP300/CBP proteins effectively inhibits KRAS signaling in PDAC, offering a new therapeutic approach with enhanced efficacy over existing BET inhibitors and potential synergy with immune checkpoint blockade.

JP2024544550APending Publication Date: 2024-12-03THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024527788
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-15
Filing Date
2022-11-15
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Current treatments for pancreatic ductal adenocarcinoma (PDAC) associated with Ras mutations are ineffective, with no curative therapies available and poor responses to chemotherapy and emerging immunotherapies, highlighting the need for new approaches to target mutant RAS-driven cancers.

Method used

Administration of a compound that inhibits bromodomain and extraterminal (BET) proteins, specifically targeting BRD4 and EP300/CBP, to disrupt oncogenic KRAS signaling, potentially combined with immune checkpoint inhibitors like PD-1/PD-L1 or CTLA-4 inhibitors.

Benefits of technology

The compound demonstrates improved efficacy compared to benchmark BET inhibitor JQ-1 and enhances tumor suppression by inhibiting KRAS signaling, reducing tumor growth and prolonging survival in preclinical models of PDAC.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544550000001_ABST
    Figure 2024544550000001_ABST
Patent Text Reader

Abstract

In accordance with the object(s) of the present disclosure, described herein is a method for treating cancer associated with a Ras mutation in a subject in need of treatment, comprising administering to the subject an effective amount of a compound of formula I as described herein or a pharma- ceutically acceptable salt thereof. The compounds described herein have improved efficacy compared to the benchmark BET inhibitor JQ-1 and have equivalent efficacy to high-dose JQ-1 for treating PDAC. In one aspect, the compounds are administered in combination with an effective amount of an immune checkpoint inhibitor, such as, for example, a PD-1 / PD-L1 inhibitor, a CTLA-4 inhibitor, or a combination thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT This invention was made with Government support under Grant Nos. I01BX004903 and IK6BX004855 awarded by the U.S. Department of Veterans Affairs. The Government has certain rights in this invention.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of and priority to co-pending U.S. Provisional Patent Application No. 63 / 279,236, filed November 15, 2021, the entire contents of which are incorporated herein by reference. [Background technology]

[0003] Mutations in the Ras gene are frequently observed in cancer patients. Mutant RAS is a driving factor in tumor initiation and maintenance. There are three human RAS genes that encode four RAS proteins: Kirsten rat sarcoma viral oncogene homolog (KRAS), neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS), and Harvey rat sarcoma viral oncogene homolog (HRAS), with two KRAS isoforms (KRAS4A and KRAS4B) arising from alternative RNA splicing. RAS proteins (KRAS4A, KRAS4B, NRAS, and HRAS) function as GDP-GTP-regulated binary on-off switches to regulate cytoplasmic signaling networks that control diverse normal cellular processes. Summary of the Invention [Problem to be solved by the invention]

[0004] One example of a cancer associated with Ras mutation is pancreatic ductal adenocarcinoma (PDAC). Currently, there is no curative therapy for patients with advanced PDAC. Although broad-spectrum chemotherapy can modestly extend survival, nearly all patients are eventually treated and overall outcomes remain poor (34). In addition, PDAC has shown poor clinical responses to newly emerging therapies, including immunotherapy, in clinical trials (35, 36). Thus, there is a need for new approaches and treatments for PDAC and other cancers associated with Ras mutations. [Means for solving the problem]

[0005] In accordance with the object(s) of the disclosure, described herein is a method for treating cancer associated with a Ras mutation in a subject in need of such treatment, comprising administering to the subject an effective amount of a compound of formula I, or a pharma- ceutically acceptable salt thereof; [ka] During the ceremony, R 12 is C1-C3 alkyl, C1-C3 haloalkyl, propylenyl, -CH2(CO)CH=CH2, oxiran-2-ylmethyl, or CH2(CO)CH2Cl; R 11 is a nitrogen-containing bicyclic or tricyclic heteroaryl, aryl, or biaryl, each of which is optionally independently selected from -N(R a )S(O)2R b , -S(O)NR a R b , -C(O)NR a R b -N(R a )C(O)R b -NR a R b , -(C1-C6 alkylenyl)R c , -(C1-C3 cycloalkylenyl)R c , aryl, heteroaryl, -(C1-C6 alkylenyl)Rc R c’ , -H, halogen, -CN, propylenyl, C1-C3 alkyl, C1-C3 haloalkyl, -OR 70 , -NR 70 R 70 , -C(O)OR 70 , -C(O)NR 70 R 70 , -S(O)2R 70 , -S(O)NR 70 R 70 , -CH2(CO)CH=CH2, oxiran-2-ylmethyl, CH2(CO)CH2Cl, and R 70 and is substituted with one, two or three substituents selected from X is optionally present and, if present, is selected from the group consisting of -O-, -C(O)-, -N(R 77 )-, and -CH(R 70 )- is selected from R 77 -H, halogen, -CN, C1-C3 haloalkyl, -OR 70 , -NR 70 R 70 , -C(O)OR 70 , -C(O)NR 70 R 70 , -S(O)2R 70 , -S(O)NR 70 R 70 , and R 70 is selected from the group consisting of R 70 each occurrence independently represents C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, C1-C6 haloalkyl, -CN, NO2, -OR e , -S(O)NR e R f , -C(O)R e , -C(O)NR e R f , -NR e R f -N(R e )C(O)R f , -(C1-C6 alkylenyl)-OR e , -(C1-C6 alkylenyl)-C(O)NR e R f, -(C1-C6 alkylenyl)-NR e R f , and -(C1-C6 alkylenyl)-N(R e )C(O)R f is selected from R a and R b each occurrence independently represents H, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 haloalkyl, R c and C1-C6 alkyl, wherein the C1-C6 alkyl is optionally selected from -OR e , -NR e R f , -C(O)OR e , -C(O)NR e R f , -S(O)2R e , -S(O)NR e R f , and R c is substituted with one substituent selected from R c and R c’ is independently selected from aryl, heteroaryl, heterocycle, cycloalkyl, and cycloalkenyl, and each R c The group optionally comprises 1, 2, 3, 4, or 5 R d is substituted with a group, R d each occurrence independently represents C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, C1-C6 haloalkyl, -CN, -NO2, -OR e , -S(O)NR e R f , -C(O)R e , -C(O)NR e R f , -NR e R f , -N(R e )C(O)R f , -(C1-C6 alkylenyl)-OR e , -(C1-C6 alkylenyl)-C(O)NR e R f , -(C1-C6 alkylenyl)-NR e R f, and -(C1-C6 alkylenyl)-N(R e )C(O)R f is selected from R e and R f is, at each occurrence, independently selected from H, C1-C6 alkyl, C1-C6 cycloalkyl, aryl, heteroaryl, and C1-C6 haloalkyl.

[0006] The compounds described herein have improved efficacy compared to the benchmark BET inhibitor JQ-1, and efficacy comparable to high dose JQ-1. In one embodiment, the compounds are administered in combination with an effective amount of an immune checkpoint inhibitor, such as, for example, a PD-1 / PD-L1 inhibitor, a CTLA-4 inhibitor, or a combination thereof.

[0007] Other systems, methods, features, and advantages of the present disclosure will be or become apparent to one skilled in the art upon review of the following figures and detailed description. All such additional systems, methods, features, and advantages are intended to be included within this description, be within the scope of the present disclosure, and be protected by the accompanying claims. In addition, all optional and preferred features and modifications of the described embodiments can be used in all aspects of the present disclosure taught herein. Furthermore, the individual features of the dependent claims, and all optional and preferred features and modifications of the described embodiments, are combinable and interchangeable with each other.

[0008] Many aspects of the present disclosure can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale, emphasis instead being placed upon clearly illustrating the principles of the present disclosure. Moreover, in the drawings, like reference numbers indicate corresponding parts throughout the several views. [Brief description of the drawings]

[0009] [Figure 1]BRD4 and EP300 / CBP are ubiquitously expressed in PDAC. (A,B) Excisional biopsies from 14 PDAC patients, including 9 with matched adjacent non-malignant tissue, were sectioned and stained for either BRD4 or EP300 / CBP. The number of positive nuclei per 40x field was quantified by 3 blinded investigators and divided by the total number of nuclei in each field. These values ​​were averaged and shown as individual value plots. (C,D) Pancreatic tumor tissues (PDAC) and adjacent non-malignant (N) PDAC patients from Badea et al. and Pei et al. were evaluated for BRD4 or EP300 mRNA expression using the Oncomine platform. All mRNA expression values ​​are plotted on a logarithmic scale. (E) Expression of BRD4 and EP300 / CBP was assessed by Western blot in human PDAC cell lines Panc1, ASPC1, MiaPaCa2, Capan1, and mouse PDAC cell line KPC-105. (F) Panc1 cells were stained for BRD4 and EP300 / CBP by immunocytochemistry. (G) Pancreatic tissues from either non-geneic wild type (WT), Pdx1-Cre×LSL-KrasG12D (KC) model of PanIN disease, Pdx1-Cre×LSL-KrasG12D×LSL-TP53R172H+ / - (KPC) model of advanced PDAC, Pdx1-Cre×LSL-KrasG12D×LSL-TP53R172H+ / + (KPPC) model of highly aggressive PDAC, or subcutaneous tumor tissues from G-68 cell-derived xenograft (CDX) model were collected and stained for either BRD4 or EP300 / CBP (*p<0.05). [Diagram 2]We show that XP-524 is a potent, multispecific BET inhibitor that engages BRD4 and EP300 / CBP. (A) Chemical structure of XP-524, designed to function as a multispecific BET inhibitor with activity against EP300 / CBP. (B, C) TR-FRET assays using either the first (BD1) or second (BD2) bromodomain of BRD4 and increasing concentrations of either the first generation BET inhibitor JQ-1 or XP-524. (D) BROMOscan assays using EP300 or its structural analog CBP and increasing concentrations of XP-524. (E) Co-crystal structure of XP-524:BRD4 (PDB:6P05) showing extensive interactions between XP-524 and the acetylated lysine pocket of the BD1 bromodomain. (F) Co-crystal structure of XP-524 with the EP300 analog CBP (XP-524:CBP) (PDB:7JUO) showing extensive interactions between XP-524 and the acetylated lysine pocket of the CBP bromodomain, as well as insertion of a sulfate moiety into the ZA loop forming a bidentate hydrogen bond with Asn-1168 and a hydrogen bond with the backbone of Asp-1116. (G) Superposition of the XP-524-CBP and XP-524-BRD4 complexes showing similar binding modes. [Diagram 3]Figure 1 shows that inhibition of EP300 / CBP enhances BETi-mediated silencing of oncogenic KRAS signaling. (A) Equal numbers of Panc1 cells were seeded in 24-well plates and treated with either DMSO vehicle, 1 μM JQ-1, JQ-1 and 1 μM SGC-CBP30, 1 μM XP-524, or XP-524 and SGC-CBP30. Cell growth was assessed every 4 hours until the control group reached 100% confluence (N=4 / group). (B) Panc1 cells were incubated with increasing concentrations of either JQ-1 or XP-524, with or without a fixed dose of 1 μM SGC-CBP30, respectively. After 48 hours, cell viability was assessed by MTT assay. (C) Panc1 cells were incubated with either DMSO vehicle, 1 μM JQ-1, JQ-1 and 1 μM SGC-CBP30, or 1 μM XP-524 and subjected to RNA sequencing. (D) Focused heatmap showing selected genes significantly changed in the cell cycle pathway using a false discovery rate (FDR) adjusted p-value of <0.05. (E) Focused heatmap showing selected genes significantly changed in the KRAS signaling pathway using a FDR adjusted p-value of <0.05. (F-H) Panc1, MiaPaCa2 (MP2), and ASPC1 cells were treated with 1 μM XP-524 and KRAS mRNA was assessed by qPCR. Values ​​are presented as fold change compared to DMSO control (C) treated samples. (I) Panc1 cells were treated again with 1 μM JQ-1, JQ-1 and 1 μM SGC-CBP30, or 1 μM XP-524 and the interaction between BRD4 and EP300 was assessed by immunoprecipitation (IP) followed by Western blot (IB). (J,K) Panc1 and KPC-105 cells were treated as described and assessed by Western blot for pRB, H3K27 acetylation, and KRAS expression and downstream activation of the MEK / ERK pathway. (L) MiaPaCa2 (MP2) and ASPC1 cells and KRAS expression and downstream MEK / ERK activation assessed by Western blot.(I-K) Excisional biopsy cores from three PDAC patients who underwent viable resection were taken, sectioned at 250 μm intervals, and cultured ex vivo in either control PBS vehicle or 5 μM XP-524. After 72 hours, slice cultures were formalin fixed, paraffin embedded, and stained for pERK or CK19 and PCNA with H&E or by immunohistochemistry. (*p<0.05). [Figure 4] XP-524 reduces mutant KRAS-induced PanIN formation in vivo. (A) Ptf1a-Cre x LSL-KrasG12D+ / - (KPC) mice were generated as a model of early pancreatic intraepithelial neoplasia (PanIN). Starting at 8 weeks of age, mice were administered daily intraperitoneal injections of either PBS vehicle or 5 mg / kg XP-524 and sacrificed at a fixed endpoint of 6 months. (B) At study endpoints, pancreatic glands were weighed and normalized to each animal's body weight, with results shown as individual value plots. (C, D) Pancreatic tissues were stained for CK19 and pancreatic amylase with H&E, Masson's Trichrome, or via immunohistochemistry, quantified as described, and results shown as individual value plots. (E, F) Tissues were also stained for mutant RASG12D, pERK, or CK19, and PCNA by immunohistochemistry. Results were quantified as described and presented as individual value plots. (G) At study endpoint, pancreatic tissue was lysed and assessed for KRAS expression and downstream activation of the MEK / ERK pathway by Western blot (*p<0.05). [Diagram 5]XP-524 extends survival and reduces pathological KRAS activation in mouse PDAC. (A) Pdx1-Cre x LSL-KrasG12D x LSL-TP53R172H+ / - (KPC) mice were generated as a model of advanced PDAC. Starting at 15 weeks of age, mice were administered daily intraperitoneal injections of either PBS vehicle or 5 mg / kg XP-524. Pancreatic tissue was collected when animals were moribund. (B) Kaplan-Meier curves showing survival of mice (N=7 / group) across both groups in days after enrollment. (C, D) Macroscopic changes in pancreatic gland structure, including gland weight, were assessed at study endpoints and normalized to the body weight of each animal, with results shown as individual value plots. Tissues were stained for pERK, E-cadherin, and PCNA, or cleaved caspase 3 by H&E or via immunohistochemistry and quantified as described, with results shown as individual value plots. (E) Pdx1-Cre x LSL-KrasG12D x LSL-TP53R172H+ / - (KPPC) mice were generated as a model of extremely aggressive PDAC. Mice were enrolled either at 2 weeks of age or when they developed 0.5 cm3 tumors. (F) Kaplan-Meier curves showing survival of mice (N=6 / group) across both groups in days after enrollment. (G,H) Macroscopic changes in pancreatic gland structure, including gland weight, were assessed at study endpoints and normalized to the body weight of each animal, with results shown as individual value plots. Tissues were also stained with H&E or via immunohistochemistry for pERK, E-cadherin, and PCNA, or cleaved caspase 3, and quantified as described, with results shown as individual value plots (*p<0.05). [Figure 6]XP-524 enhances T cell recruitment but does not promote a functional antitumor immune response. (A, B) Pdx1-Cre x LSL-KrasG12D x LSL-TP53R172H+ / - (KPC) mice were generated as a model of advanced PDAC. Starting at 15 weeks of age, mice were administered daily intraperitoneal injections of either PBS vehicle or 5 mg / kg XP-524. When animals were moribund, pancreatic tissue was collected and stained via H&E, or immunohistochemistry for E-cadherin and the T cell surrogate CD3, or CD3 and the T cell exhaustion marker PD-1. Tissue sections were quantified as described and shown as individual value plots. (C) KPC were enrolled as described and treated with either PBS vehicle or 5 mg / kg XP-524. After 2 months of treatment, tumor tissues were collected and analyzed by flow cytometry for tumor-infiltrating CD4+ and CD8+ T cells, respectively (N=4 / group). (D) Tumor-infiltrating cells were gated based on CD8 staining as previously shown, and the total number of cells positive for IFNγ is shown as an individual value plot. (E) The total number of cells positive for either CD4 or CD8, and the T cell exhaustion marker PD-1 from tumors of PBS and XP-524 treated mice. (F) Tumor-infiltrating T cells were gated based on CD4 staining, and analyzed for CD25 and FoxP3, and the total number of CD4+CD25+FoxP3 regulatory T cells is shown as an individual value plot. (G,H) Panc1 cells were treated with either DMSO vehicle or 1 μM XP-524, and analyzed by RNA sequencing and subjected to gene set enrichment analysis, revealing significant enrichment in antigen processing and presentation pathways. (I) Tissues from KPC mice treated with either PBS or XP-524 were stained for MHC class 1 via immunohistochemistry and representative images are shown. (J,K) RNA sequencing and gene set enrichment analysis of Panc1 treated as described revealing significant downregulation of the TGFβ signaling pathway. (L) Homogenized tumor tissue or serum from KPC mice treated with either PBS or XP-524 were analyzed for levels of TGFβ1 by ELISA. (*p<0.05) [Figure 7]XP-524 shows that in cooperation with PD-1 inhibition, it further extends survival in KPC mice. (A) Pdx1-Cre x LSL-KrasG12D x LSL-TP53R172H+ / - (KPC) mice were generated as a model of advanced PDAC. Starting at 15 weeks of age, mice were administered either twice weekly intraperitoneal injections of 200 μg anti-PD-1 (N=7) or daily injections of 5 mg / kg XP-524 along with twice weekly injections of anti-PD-1 (N=11). The study was terminated if animals showed signs of disease-associated morbidity. (B) Kaplan-Meier curves showing survival of mice across both groups in days after enrollment. (C-E) Pancreatic tissue was collected at study endpoints and stained for pan-leukocyte markers CD45 or E-cadherin, and T cell surrogate CD3, either by H&E or via immunohistochemistry. Tissues were quantified as described, and counts are shown as individual value plots. (F) Tumor tissues were also stained for cytotoxic T cell markers CD8, CK19, and granzyme B, or the apoptotic surrogate cleaved caspase 3. (G) KPC mice were enrolled as described and treated with either anti-PD-1, or XP-524 and anti-PD-1. After 2 months of treatment, tumor tissues were collected and analyzed by flow cytometry for tumor-infiltrating CD4+ and CD8+ T cells, respectively (N=4 / group). (H) Tumor-infiltrating cells were gated based on CD8 staining as previously shown, and the total number of cells positive for IFNγ is shown as individual value plots. (I) The total number of cells positive for either CD4 or CD8, and the T cell exhaustion marker PD-1 from tumors of anti-PD-1 and XP-524+anti-PD-1 treated mice. (J) Tumor-infiltrating T cells were gated based on CD4 staining and analyzed for CD25 and FoxP3, with the total number of CD4+CD25+FoxP3 regulatory T cells shown as individual value plots. (K) Spleen and tumor-infiltrating cells were gated based on CD8 and CD4 staining shown above, and CD8+ events were isolated and analyzed for expression of the cytotoxic T cell activation marker perforin. The total number of cells positive for both CD8 and perforin is shown as individual value plots.(L) Tumor-infiltrating CD8+ cells were gated as before and analyzed for co-expression of previously described T cell activation markers, including perforin and IFNγ. The numbers of CD8+perforin+IFNγ+ cells from each group are shown as individual value plots (*p<0.05). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] Many modifications and other embodiments of the disclosed compositions and methods will occur to those skilled in the art having the benefit of the teachings presented in the foregoing description and the associated drawings. It is therefore to be understood that the disclosure is not limited to the specific embodiments disclosed, and modifications and other embodiments are intended to be included within the scope of the appended claims. Those skilled in the art will recognize many variations and adaptations of the aspects described herein. These variations and adaptations are intended to be included within the teachings of the disclosure and encompassed by the claims of this specification.

[0011] Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.

[0012] As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has individual components and features that may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the disclosure.

[0013] Any recited method may be carried out in the order of events recited or in any other order that is logically possible. That is, unless expressly stated otherwise, it is in no way intended that any method or aspect described herein be construed as requiring that its steps be performed in a particular order. Thus, the method claims are in no way intended to imply an order in any respect unless the steps are specifically recited in the claims or description as being limited to a particular order. This is to be maintained for any possible implicit basis for interpretation, including the obvious meaning derived from the arrangement of steps or operational flow, grammatical construction or punctuation, or logical matters regarding the number or type of aspects described in the specification.

[0014] All publications mentioned herein are incorporated by reference as if disclosed and described in connection with the methods and / or materials for which the publications are cited. The publications discussed herein are provided solely for their disclosure prior to the filing date of this application. Nothing herein should be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publications provided herein may be different from the actual publication dates and may be independently confirmed.

[0015] Although aspects of the present disclosure may be described and claimed in particular statutory classes, such as statutory classes, this is for convenience only, and those of skill in the art will understand that each aspect of the present disclosure may be described and claimed in any statutory class.

[0016] It should also be understood that the terms used herein are only for describing certain aspects and are not intended to be limiting.Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the disclosed compositions and methods belong.Terms such as those defined in commonly used dictionaries should be interpreted to have a meaning consistent with their meaning in the context of this specification and related art, and should not be interpreted in an ideal or overly formal sense unless otherwise explicitly defined herein.

[0017] Prior to describing the various aspects of this disclosure, the following definitions are provided and should be used unless otherwise indicated. Additional terms may be defined elsewhere in this disclosure.

[0018] definition As used herein, "comprising" is to be interpreted as specifying the presence of the features, integers, steps, or components described as referenced, but does not exclude the presence or addition of one or more features, integers, steps, or components, or groups thereof. Additionally, the terms "by," "comprising," "comprises," "comprised of," "including," "includes," "included," "involving," "involves," "involved," and "such as" are each used in their open, non-limiting sense and may be used interchangeably. Additionally, the term "comprising" is intended to include examples and embodiments encompassed by the terms "consisting essentially of" and "consisting of." Similarly, the term "consisting essentially of" is intended to include examples encompassed by the term "consisting of."

[0019] As used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to an "excipient" includes, but is not limited to, mixtures or combinations of two or more such excipients.

[0020] It should be noted that ratios, concentrations, amounts, and other numerical data may be expressed herein in a range format. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint and independently of the other endpoint. Also, it is understood that certain values ​​are disclosed herein, and that each value is also disclosed herein as "about" that particular value in addition to the value itself. For example, if a value of "10" is disclosed, "about 10" is also disclosed. Ranges may be expressed herein as "about" one particular value and / or to "about" another particular value. Similarly, when values ​​are expressed as approximations by use of the antecedent "about," it is understood that the particular value forms a further aspect. For example, if a value of "about 10" is disclosed, "10" is also disclosed.

[0021] When a range is expressed, a further embodiment includes from the one particular value and / or to the other particular value. For example, when a stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure, e.g., the phrase "from x to y" includes ranges from "x" to "y", as well as ranges from greater than "x" and less than "y". Ranges may also be expressed as upper limits, e.g., "about x, y, z, or less", which should be interpreted to include the specific ranges of "about x", "about y", and "about z", as well as the ranges "less than x", "less than y", and "less than z". Similarly, the phrase "about x, y, z, or more" should be interpreted to include the specific ranges of "about x", "about y", and "about z", as well as the ranges "more than x", "more than y", and "more than z". In addition, when "x" and "y" are numerical values, the phrase "about 'x' to 'y'" includes about "x" to about "y".

[0022] It should be understood that such range formats are used for convenience and brevity and should thus be interpreted flexibly to include not only the numerical values ​​explicitly recited as the limits of the range, but also all individual numerical values ​​or subranges subsumed within that range, as if each numerical value and subrange were explicitly recited. To illustrate, a numerical range of "about 0.1% to 5%" should be interpreted not only to include the explicitly recited values ​​of about 0.1% to about 5%, but also to include the individual values ​​(e.g., about 1%, about 2%, about 3%, and about 4%) and subranges (e.g., about 0.5% to about 1.1%, about 5% to about 2.4%, about 0.5% to about 3.2%, and about 0.5% to about 4.4%, as well as other possible subranges) within the indicated range. Thus, for example, if a component is in an amount of about 1%, 2%, 3%, 4%, or 5%, and any value can be the lower and upper endpoints of a range, any range from 1% to 5% (e.g., 1% to 3%, 2% to 4%, etc.) is contemplated.

[0023] As used herein, the terms "about," "approximately," "nearly," and "substantially" mean that the quantity or value in question may be an exact value or may be a value that provides an equivalent result or effect as recited in the claims or taught herein. That is, it is understood that the amounts, sizes, formulations, parameters, and other quantities and characteristics are not and need not be exact, but may be approximate and / or may be larger or smaller, as desired, to reflect tolerances, conversion factors, rounding, measurement errors, and the like, and other factors known to those skilled in the art, such that equivalent results or effects are obtained. In some circumstances, values ​​that provide equivalent results or effects cannot be reasonably determined. In such cases, "about" and "approximately" are generally understood to mean nominal values ​​that exhibit a variation of ±10%, unless otherwise indicated or implied. In general, a quantity, size, formulation, parameter, or other quantity or characteristic is "about," "approximately," or "nearly," regardless of whether it is expressly described as such. When "about," "approximately," or "approximately" is used in front of a quantitative value, it is understood that the parameter also includes the particular quantitative value itself, unless specifically stated otherwise.

[0024] As used herein, "IC 50 " is intended to refer to the concentration of a substance (e.g., a compound or drug) required for 50% inhibition of a biological process, or a component of a process. For example, IC 50 refers to the half-maximal (50%) inhibitory concentration (IC) of a substance, as determined in a suitable assay.

[0025] A residue of a chemical species, as used herein and in the concluding claims, refers to a moiety that is a product resulting from a chemical species in a particular reaction scheme, or a subsequent formulation or chemical product, regardless of whether that moiety is actually derived from the chemical species. Thus, an ethylene glycol residue in a polyester refers to one or more -OCH2CH2O- units in the polyester, regardless of whether ethylene glycol is used to prepare the polyester. Similarly, a sebacic acid residue in a polyester refers to one or more -CO(CH2)8CO- moieties in the polyester, regardless of whether that residue is derived by reacting sebacic acid or an ester thereof to obtain the polyester.

[0026] As used herein, the term "substituted" is intended to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, and aromatic and nonaromatic substituents of organic compounds. Exemplary substituents include, for example, those described below. The permissible substituents can be one or more and can be the same or different for suitable organic compounds. For purposes of this disclosure, heteroatoms such as nitrogen can have hydrogen substituents and / or any permissible substituents of organic compounds described herein that satisfy the valence of the heteroatom. This disclosure is not intended to be limited in any manner by the permissible substituents of organic compounds. The terms "substituted" or "substituted with" also include the implicit proviso that such substitution is subject to the permissible valences of the substituted atom and substituent, and that the substitution results in a stable compound, e.g., a compound that does not spontaneously undergo transformation by rearrangement, cyclization, elimination, and the like. It is also contemplated that in certain embodiments, unless expressly indicated to the contrary, individual substituents may be further optionally substituted (i.e., may be further substituted or unsubstituted).

[0027] The position of the substituents can be defined relative to the position of other substituents in the aromatic ring. For example, as shown below in relation to an "R" group, a second substituent can be "ortho", "para", or "meta" to the R group, meaning that the second substituent is attached to the carbon labeled ortho, para, or meta as shown below. Combinations of ortho, para, and meta substituents for a given group or substituent are also contemplated and should be considered disclosed. [ka]

[0028] In the definitions of various terms, "A 1 ","A 2 ","A 3 " and "A 4 " is used herein as a general symbol to represent various specific substituents. These symbols are not limited to those disclosed herein and may be any substituent, and if they are defined as a certain substituent in one instance, they may be defined as some other substituent in another instance.

[0029] As used herein, the terms "aliphatic" or "aliphatic group" refer to a hydrocarbon moiety that may be straight-chained (i.e., unbranched), branched-chained, or cyclic (including fused, bridged, and spiro-fused polycyclic), and may be fully saturated or may contain one or more units of unsaturation, but is not aromatic. Unless otherwise indicated, aliphatic groups contain 1-20 carbon atoms. Aliphatic groups include, but are not limited to, linear or branched alkyl, alkenyl, and alkynyl groups, as well as hybrids thereof, such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl, or (cycloalkyl)alkenyl.

[0030] The term "alkyl" as used herein refers to a branched or unbranched saturated hydrocarbon group of 1 to 24 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, t-butyl, n-pentyl, isopentyl, s-pentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl, tetradecyl, hexadecyl, eicosyl, tetracosyl, and the like. The alkyl group can be cyclic or acyclic. The alkyl group can be branched or unbranched. The alkyl group can also be substituted or unsubstituted. For example, the alkyl group can be substituted with one or more groups, including, but not limited to, alkyl, cycloalkyl, alkoxy, amino, ether, halide, hydroxy, nitro, silyl, sulfo-oxo, or thiol, as described herein. A "lower alkyl" group is an alkyl group containing 1 to 6 (e.g., 1 to 4) carbon atoms. The term alkyl group can also be C1 alkyl, C1-C2 alkyl, C1-C3 alkyl, C1-C4 alkyl, C1-C5 alkyl, C1-C6 alkyl, C1-C7 alkyl, C1-C8 alkyl, C1-C9 alkyl, C1-C10 alkyl, etc., including up to C1-C24 alkyl.

[0031] Throughout this specification, "alkyl" is used generally to refer to both unsubstituted and substituted alkyl groups, however, substituted alkyl groups are also specifically referred to herein by identifying the particular substituent(s) on the alkyl group. For example, the term "halogenated alkyl" or "haloalkyl" specifically refers to an alkyl group that is substituted with one or more halides, such as fluorine, chlorine, bromine, or iodine. Alternatively, the term "monohaloalkyl" specifically refers to an alkyl group that is substituted with a single halide, such as fluorine, chlorine, bromine, or iodine. The term "polyhaloalkyl" specifically refers to an alkyl group that is independently substituted with two or more halides, i.e., each halide substituent need not be the same halide as another halide substituent, nor do multiple instances of a halide substituent have to be on the same carbon. The term "alkoxyalkyl" specifically refers to an alkyl group that is substituted with one or more alkoxy groups, as described below. The term "aminoalkyl" specifically refers to an alkyl group that is substituted with one or more amino groups. The term "hydroxyalkyl" specifically refers to an alkyl group substituted with one or more hydroxy groups. Where "alkyl" is used in one instance and a specific term such as "hydroxyalkyl" is used in another instance, the term "alkyl" is not meant to imply that the specific term also includes "hydroxyalkyl."

[0032] This convention is also used for other groups described herein. That is, a term such as "cycloalkyl" refers to both unsubstituted and substituted cycloalkyl moieties, but substituted moieties may additionally be specifically identified herein, e.g., a particular substituted cycloalkyl may be specifically referred to as, e.g., an "alkylcycloalkyl". Similarly, a substituted alkoxy may be specifically referred to as, e.g., a "halogenated alkoxy", a particular substituted alkenyl may be, e.g., an "alkenylalcohol", etc. Again, the convention of using a general term such as "cycloalkyl" and a specific term such as "alkylcycloalkyl" is not meant to imply that the general term does not include the specific term.

[0033] The term "cycloalkyl" as used herein is a non-aromatic carbon-based ring composed of at least three carbon atoms. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl, etc. The term "heterocycloalkyl" is a cycloalkyl group of the type defined above, included within the meaning of the term "cycloalkyl", in which at least one of the carbon atoms of the ring is replaced with a heteroatom, such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus. Cycloalkyl and heterocycloalkyl groups can be substituted or unsubstituted. Cycloalkyl and heterocycloalkyl groups can be substituted with one or more groups, including, but not limited to, alkyl, cycloalkyl, alkoxy, amino, ether, halide, hydroxy, nitro, silyl, sulfo-oxo, or thiol, as described herein.

[0034] The term "alkanediyl" as used herein refers to a divalent saturated aliphatic group having one or two saturated carbon atoms as the point(s) of attachment, of a linear or branched cyclo, cyclic, or acyclic structure, no carbon-carbon double or triple bonds, and no atoms other than carbon and hydrogen. -CH2-(methylene), -CH2CH2-, -CH2C(CH3)2CH2-, and -CH2CH2CH2- groups are non-limiting examples of alkanediyl groups.

[0035] The terms "alkoxy" and "alkoxyl" are used herein to refer to an alkyl or cycloalkyl group bonded through an ether linkage, i.e., an "alkoxy" group is -OA 1 where A 1 is alkyl or cycloalkyl as defined above. "Alkoxy" also includes polymeric alkoxy groups as just described, i.e., alkoxy includes -OA, -O, -O-C, -O-H ... 1 -OA 2 OR-OA 1 -(OA 2 ) a -OA 3 and the like, where "a" is an integer from 1 to 200, and A 1 , A 2 , and A 3 is an alkyl and / or cycloalkyl group.

[0036] The term "alkenyl" as used herein refers to a hydrocarbon group of 2 to 24 carbon atoms having a structural formula containing at least one carbon-carbon double bond. 1 A 2 )C=C(A 3 A 4Asymmetric structures such as aryl, aryl, aryl, aryls ...

[0037] The term "cycloalkenyl" as used herein is a non-aromatic carbon-based ring composed of at least three carbon atoms and containing at least one carbon-carbon double bond, i.e., C=C. Examples of cycloalkenyl groups include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, norbornenyl, and the like. The term "heterocycloalkenyl" is a cycloalkenyl group of the type defined above, included within the meaning of the term "cycloalkenyl", in which at least one of the carbon atoms of the ring is replaced with a heteroatom, such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus. Cycloalkenyl and heterocycloalkenyl groups can be substituted or unsubstituted. The cycloalkenyl and heterocycloalkenyl groups can be substituted with one or more groups including, but not limited to, alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, azide, nitro, silyl, sulfo-oxo, or thiol, as described herein.

[0038] The term "alkynyl" as used herein is a hydrocarbon group of 2 to 24 carbon atoms having a structural formula containing at least one carbon-carbon triple bond. Alkynyl groups can be unsubstituted or substituted with one or more groups, including, but not limited to, alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, azide, nitro, silyl, sulfo-oxo, or thiol, as described herein.

[0039] The term "cycloalkynyl" as used herein is a non-aromatic carbon-based ring composed of at least seven carbon atoms and containing at least one carbon-carbon triple bond. Examples of cycloalkynyl groups include, but are not limited to, cyclooctynyl, cyclononynyl, and the like. The term "heterocycloalkynyl" is a cycloalkenyl group of the type defined above, included within the meaning of the term "cycloalkynyl", in which at least one of the carbon atoms of the ring is replaced with a heteroatom, such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus. Cycloalkynyl and heterocycloalkynyl groups can be substituted or unsubstituted. Cycloalkynyl and heterocycloalkynyl groups can be substituted with one or more groups, including, but not limited to, alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, azide, nitro, silyl, sulfo-oxo, or thiol, as described herein.

[0040] As used herein, the term "aromatic group" refers to a ring structure having a cyclic cloud of delocalized π-electrons above and below the plane of the molecule, the π-cloud containing (4n+2) π-electrons. Further discussion of aromaticity is found in Morrison and Boyd, Organic Chemistry, (5th Ed., 1987), Chapter 13, entitled "Aromaticity," pages 477-497, which is incorporated herein by reference. The term "aromatic group" includes both aryl and heteroaryl groups.

[0041] As used herein, the term "aryl" refers to a group that contains any carbon-based aromatic group, including, but not limited to, benzene, naphthalene, phenyl, biphenyl, anthracene, and the like. The aryl group may be substituted or unsubstituted. The aryl group may be substituted with one or more groups, including, but not limited to, alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, -NH2, carboxylic acid, ester, ether, halide, hydroxy, ketone, azide, nitro, silyl, sulfo-oxo, or thiol, as described herein. The term "biaryl" is a specific type of aryl group and is included in the definition of "aryl". In addition, aryl groups can include multiple ring structures that can be a single ring structure or that are either fused ring structures or are linked through one or more bridging groups, such as carbon-carbon bonds. For example, biaryl can be two aryl groups that are linked together through a fused ring structure, as in naphthalene, or are linked through one or more carbon-carbon bonds, as in biphenyl. Fused aryl groups are also contemplated, including, but not limited to, indene and naphthalene groups.

[0042] The term "aldehyde" as used herein is represented by the formula -C(O)H. Throughout this specification, "C(O)" is a shorthand notation for a carbonyl group, i.e., C=O.

[0043] As used herein, the term "amine" or "amino" refers to a group of the formula -NA 1 A 2 In the formula, A 1 and A 2 may independently be hydrogen or an alkyl, cycloalkyl, alkenyl, cycloalkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein. A particular example of amino is -NH2.

[0044] The term "alkylamino" as used herein is represented by the formula -NH(-alkyl) and -N(-alkyl), where alkyl is as described herein. Representative examples include, but are not limited to, methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, (sec-butyl)amino, (tert-butyl)amino, pentylamino, isopentylamino, (tert-pentyl)amino, hexylamino, dimethylamino, diethylamino, dipropylamino, diisopropylamino, dibutylamino, diisobutylamino, di(sec-butyl)amino, di(tert-butyl)amino, dipentylamino, diisopentylamino, di(tert-pentyl)amino, dihexylamino, N-ethyl-N-methylamino, N-methyl-N-propylamino, N-ethyl-N-propylamino, and the like.

[0045] The term "carboxylic acid" as used herein is represented by the formula --C(O)OH.

[0046] As used herein, the term "ester" refers to an ester of the formula -OC(O)A 1 or -C(O)OA 1 In the formula, A 1 can be an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein.

[0047] As used herein, the term "ether" refers to a compound of formula A 1 Office Automation 2 In the formula, A 1 and A 2 can be independently an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein.

[0048] As used herein, the terms “halo,” “halogen,” or “halide,” which may be used interchangeably, refer to F, Cl, Br, or I.

[0049] As used herein, the terms "pseudohalide," "pseudohalogen," or "pseudohalo" may be used interchangeably and refer to functional groups that behave substantially similarly to halides. Such functional groups include, by way of example, cyano, thiocyanato, azido, trifluoromethyl, trifluoromethoxy, perfluoroalkyl, and perfluoroalkoxy groups.

[0050] The term "heteroalkyl" as used herein refers to an alkyl group containing at least one heteroatom. Suitable heteroatoms include, but are not limited to, O, N, Si, P, and S, with nitrogen, phosphorus, and sulfur atoms being optionally oxidized, and nitrogen heteroatoms being optionally quaternized. Heteroalkyl can be substituted as defined above for alkyl groups.

[0051] The term "heteroaryl" as used herein refers to an aromatic group having at least one heteroatom incorporated within the ring of the aromatic group. Examples of heteroatoms include, but are not limited to, nitrogen, oxygen, sulfur, and phosphorus, with N-oxides, sulfur oxides, and dioxides being permissible heteroatom substitutions. Heteroaryl groups can be substituted or unsubstituted. Heteroaryl groups can be substituted with one or more groups, including, but not limited to, alkyl, cycloalkyl, alkoxy, amino, ether, halide, hydroxy, nitro, silyl, sulfo-oxo, or thiol, as described herein. Heteroaryl groups can be monocyclic or alternatively fused ring systems. Heteroaryl groups include, but are not limited to, furyl, imidazolyl, pyrimidinyl, tetrazolyl, thienyl, pyridinyl, pyrrolyl, N-methylpyrrolyl, quinolinyl, isoquinolinyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, isothiazolyl, pyridazinyl, pyrazinyl, benzofuranyl, benzodioxolyl, benzothiophenyl, indolyl, indazolyl, benzimidazolyl, imidazopyridinyl, pyrazolopyridinyl, and pyrazolopyrimidinyl. Further non-limiting examples of heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiophenyl, pyrazolyl, imidazolyl, benzo[d]oxazolyl, benzo[d]thiazolyl, quinolinyl, quinazolinyl, indazolyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, benzo[c][1,2,5]thiadiazolyl, benzo[c][1,2,5]oxadiazolyl, and pyrido[2,3-b]pyrazinyl.

[0052] As used herein, the terms "heterocycle" or "heterocyclyl" may be used interchangeably and refer to monocyclic and polycyclic aromatic or non-aromatic ring systems in which at least one of the ring members is other than carbon. Thus, this term includes, but is not limited to, "heterocycloalkyl," "heteroaryl," "bicyclic heterocycle," and "polycyclic heterocycle." Examples of the heterocycle include pyridine, pyrimidine, furan, thiophene, pyrrole, isoxazole, isothiazole, pyrazole, oxazole, thiazole, imidazole, oxazoles including 1,2,3-oxadiazole, 1,2,5-oxadiazole, and 1,3,4-oxadiazole, thiadiazoles including 1,2,3-thiadiazole, 1,2,5-thiadiazole, and 1,3,4-thiadiazole, triazoles including 1,2,3-triazole and 1,3,4-triazole, tetrazoles including 1,2,3,4-tetrazole and 1,2,4,5-tetrazole, pyridazine, pyrazine, triazines including 1,2,4-triazine and 1,3,5-triazine, tetrazines including 1,2,4,5-tetrazine, pyrrolidine, piperidine, piperazine, morpholine, azetidine, tetrahydropyran, tetrahydrofuran, and dioxane. The term heterocyclyl group can also be C2 heterocyclyl, C2-C3 heterocyclyl, C2-C4 heterocyclyl, C2-C5 heterocyclyl, C2-C6 heterocyclyl, C2-C7 heterocyclyl, C2-C8 heterocyclyl, C2-C9 heterocyclyl, C2-C10 heterocyclyl, C2-C11 heterocyclyl, etc., including up to C2-C18 heterocyclyl. For example, C2 heterocyclyl includes groups having two carbon atoms and at least one heteroatom, including, but not limited to, aziridinyl, diazetidinyl, dihydrodiazetyl, oxiranyl, thiiranyl, etc. Alternatively, for example, C5 heterocyclyl includes groups having five carbon atoms and at least one heteroatom, including, but not limited to, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, diazepanyl, pyridinyl, etc.It is understood that heterocyclyl groups may be attached, if chemically possible, either through a heteroatom within the ring or through one of the carbons comprising the heterocyclyl ring.

[0053] The term "bicyclic heterocycle" or "bicyclic heterocyclyl" as used herein refers to a ring system in which at least one of the ring members is other than carbon. Bicyclic heterocyclyl includes ring systems in which an aromatic ring is fused to another aromatic ring or an aromatic ring is fused to a non-aromatic ring. Bicyclic heterocyclyl includes ring systems in which a benzene ring is fused to a 5- or 6-membered ring containing 1, 2, or 3 ring heteroatoms, or a pyridine ring is fused to a 5- or 6-membered ring containing 1, 2, or 3 ring heteroatoms. Bicyclic heterocyclic groups include, but are not limited to, indolyl, indazolyl, pyrazolo[1,5-a]pyridinyl, benzofuranyl, quinolinyl, quinoxalinyl, 1,3-benzodioxolyl, 2,3-dihydro-1,4-benzodioxinyl, 3,4-dihydro-2H-chromenyl, 1H-pyrazolo[4,3-c]pyridin-3-yl; 1H-pyrrolo[3,2-b]pyridin-3-yl; and 1H-pyrazolo[3,2-b]pyridin-3-yl.

[0054] The term "heterocycloalkyl" as used herein refers to an aliphatic, partially unsaturated or fully saturated 3-14 membered ring system, including monocyclic rings of 3-8 atoms, as well as bicyclic and tricyclic ring systems. Heterocycloalkyl ring systems contain 1-4 heteroatoms independently selected from oxygen, nitrogen, and sulfur, where the nitrogen and sulfur heteroatoms can be optionally oxidized and the nitrogen heteroatom can be optionally substituted. Representative heterocycloalkyl groups include, but are not limited to, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl.

[0055] The term "hydroxyl" or "hydroxy" as used herein is represented by the formula --OH.

[0056] As used herein, the term "ketone" refers to a compound of formula A 1 C(O)A 2 In the formula, A 1 and A 2 can be independently an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein.

[0057] The term "azide" or "azide" as used herein is represented by the formula --N3.

[0058] The term "nitro" as used herein is represented by the formula --NO.sub.2.

[0059] The term "nitrile" or "cyano" as used herein is represented by the formula --CN.

[0060] As used herein, the term "silyl" refers to a group of the formula -SiA 1 A 2 A 3 In the formula, A 1 , A 2 , and A 3 may be independently hydrogen or an alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein.

[0061] As used herein, the term "sulfo-oxo" refers to a group of the formula -S(O)A 1 , -S(O)2A 1 , -OS(O)2A 1 , or -OS(O)2OA 1 In the formula, A 1may be hydrogen or an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein. Throughout this specification, "S(O)" is a shorthand notation for S=O. The term "sulfonyl" is used herein to refer to a group of the formula -S(O)A 1 is used to refer to a sulfo-oxo group represented by the formula: 1 may be hydrogen or an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein. As used herein, the term "sulfone" refers to a group of formula A 1 S(O)2A 2 In the formula, A 1 and A 2 may be independently an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein. As used herein, the term "sulfoxide" refers to a group of the formula A 1 S(O)A 2 In the formula, A 1 and A 2 can be independently an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein.

[0062] The term "thiol" as used herein is represented by the formula --SH.

[0063] "R 1 ", "R 2 ", "R 3 " ... where n is an integer "R n " as used herein may independently have one or more of the groups listed above. For example, R 1When is a straight chain alkyl group, one of the hydrogen atoms of the alkyl group can be optionally replaced with a hydroxyl group, an alkoxy group, an alkyl group, a halide, etc. Depending on the group selected, the first group can be embedded within the second group, or alternatively, the first group can be pendant (i.e., attached) to the second group. For example, in the phrase "an alkyl group comprising an amino group," the amino group can be embedded within the backbone of the alkyl group. Alternatively, the amino group can be attached to the backbone of the alkyl group. The nature of the group(s) selected will determine whether the first group is embedded or attached to the second group.

[0064] As described herein, the compounds of the present invention may contain "optionally substituted" moieties. In general, the term "substituted", whether preceded by the term "optionally", means that one or more hydrogens of the specified moiety are replaced with a suitable substituent. Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituents may be the same or different at all positions. Combinations of substituents envisioned by the present invention are preferably those that result in the formation of stable or chemically feasible compounds. In certain embodiments, it is also contemplated that individual substituents may be further optionally substituted (i.e., further substituted or not substituted), unless otherwise expressly indicated to the contrary.

[0065] The term "stable," as used herein, refers to compounds that are substantially unchanged when subjected to conditions that enable their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.

[0066] Suitable monovalent substituents on a substitutable carbon atom of an "optionally substituted" group are independently halogen; -(CH) 0-4 R°;-(CH2)0-4 OR°;-O(CH2) 0-4 R°, -O-(CH2) 0-4 C(O)OR°;-(CH2) 0-4 CH(OR°)2;-(CH2) 0-4 SR°; may be substituted with R° -(CH2) 0-4 Ph; R° may be substituted -(CH2) 0-4 O(CH2) 0-1 Ph; may be substituted with R° -CH=CHPh; may be substituted with R° -(CH2) 0-4 O(CH2) 0-1 -Pyridyl; -NO2; -CN; -N3; ​​-(CH2) 0-4 N(R°)2;-(CH2) 0-4 N(R°)C(O)R°;-N(R°)C(S)R°;-(CH2) 0-4 N(R°)C(O)NR°2;-N(R°)C(S)NR°2;-(CH2) 0-4 N(R°)C(O)OR°;-N(R°)N(R°)C(O)R°;-N(R°)N(R°)C(O)NR°2;-N(R°)N(R°)C(O)OR°;-(CH2) 0-4 C(O)R°;-C(S)R°;-(CH2) 0-4 C(O)OR°;-(CH2) 0-4 C(O)SR°;-(CH2) 0-4 C(O)OSiR°3;-(CH2) 0-4 OC(O)R°;-OC(O)(CH2) 0-4 SR-, SC(S)SR°;-(CH2) 0-4 SC(O)R°;-(CH2) 0-4 C(O)NR°2;-C(S)NR°2;-C(S)SR°;-(CH2) 0-4 OC(O)NR°2;-C(O)N(OR°)R°;-C(O)C(O)R°;-C(O)CH2C(O)R°;-C(NOR°)R°;-(CH2) 0-4 SSR°;-(CH2) 0-4 S(O)2R°;-(CH2) 0-4 S(O)2OR°;-(CH2) 0-4 OS(O)2R°;-S(O)2NR°2;-(CH2) 0-4S(O)R°;-N(R°)S(O)2NR°2;-N(R°)S(O)2R°;-N(OR°)R°;-C(NH)NR°2;-P(O)2R°;-P(O)R°2;-OP(O)R°2;-OP(O)(OR°)2;SiR°3;-(C 1-4 Linear or branched alkylene)ON(R°)2; or -(C 1-4 linear or branched alkylene)C(O)ON(R°), where each R° may be substituted as defined below and is independently hydrogen, C 1-6 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph, -CH2- (a 5-6 membered heteroaryl ring), or a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or, notwithstanding the above definition, two independent occurrences of R° taken together with their intervening atom(s) form a 3-12 membered saturated, partially unsaturated, or aryl monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0067] Suitable monovalent substituents on R° (or the ring formed by two independent occurrences of R° together with their intervening atoms) are independently halogen, -(CH2), 0-2 R ● , -(Halo R ● ), -(CH2) 0-2 OH, -(CH2) 0-2 OR ● , -(CH2) 0-2 CH(OR ● )2;-O(HaloR ● ), -CN, -N3, -(CH2) 0-2 C(O)R ● , -(CH2) 0-2 C(O)OH, -(CH2) 0-2 C(O)OR ● , -(CH2) 0-2 S.R. ● , -(CH2) 0-2 SH, -(CH2) 0-2 NH2, -(CH2) 0-2 NHR ● , -(CH2)0-2 NR ● 2, -NO2, -SiR ● 3. -OSiR ● 3. -C(O)SR ● , -(C 1-4 Linear or branched alkylene)C(O)OR ● , or -SSR ● where each R ● is unsubstituted or, if preceded by "halo", is substituted only with one or more halogens, and independently, C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph is a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents on a saturated carbon atom of R° include =O and =S.

[0068] Suitable divalent substituents on a saturated carbon atom of an "optionally substituted" group include the following: =O, =S, =NNR * 2, =NNHC(O)R * , =NNHC(O)OR * , =NNHS(O)2R * , =NR * , =NOR * , -O(C(R * 2)) 2-3 O- or -S(C(R * 2)) 2-3 S-, wherein R * Each independent occurrence of 1-6 Aliphatic or unsubstituted 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Preferred divalent substituents attached to the adjacent substitutable carbon of the "optionally substituted" group include -O(CR * 2) 2-3 O-, wherein R * Each independent occurrence of 1-6It is selected from aliphatic or unsubstituted 5-6 membered saturated, partially unsaturated, or aryl rings having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0069] R * Suitable substituents on the aliphatic group include halogen, -R ● , -(Halo R ● ), -OH, -OR ● , -O(HaloR ● ), -CN, -C(O)OH, -C(O)OR ● , -NH2, -NHR ● , -NR ● 2, or -NO2, wherein each R ● is unsubstituted or, if preceded by "halo", is substituted only with one or more halogens, and independently, C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph, or a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0070] Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include -R † , -NR † 2. -C(O)R † , -C(O)OR † , -C(O)C(O)R † , -C(O)CH2C(O)R † , -S(O)2R † , -S(O)NR † 2. -C(S)NR † 2. -C(NH)NR † 2, or -N(R † )S(O)2R † In the formula, each R † are independently hydrogen, C which may be substituted as defined below 1-6 aliphatic, unsubstituted -OPh, or an unsubstituted 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or, notwithstanding the above definitions, R† two independent occurrences of together with their intervening atom(s) form an unsubstituted 3-12 membered saturated, partially saturated, or aryl monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0071] R † Suitable substituents on the aliphatic groups are independently halogen, -R ● , -(Halo R ● ), -OH, -OR ● , -O(HaloR ● ), -CN, -C(O)OH, -C(O)OR ● , -NH2, -NHR ● , -NR ● 2, or -NO2, where each R ● is unsubstituted or, if preceded by "halo", is substituted only with one or more halogens, and independently, C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph, or a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0072] The term "leaving group" refers to an atom (or group of atoms) having electron-withdrawing capability that can be displaced as a stable species with the bonding electrons. Examples of suitable leaving groups include halides and sulfonate esters, including, but not limited to, triflates, mesylates, tosylates, and brosylates.

[0073] The compounds described herein contain one or more double bonds and may thus potentially occur as cis / trans (E / Z) isomers, as well as other conformational isomers, and unless stated to the contrary, the present invention includes all such possible isomers, as well as mixtures of such isomers.

[0074] Unless stated to the contrary, formulas with chemical bonds shown only as solid lines and not as wedges or dashed lines contemplate each possible isomer, e.g., each enantiomer and diastereomer, as well as mixtures of isomers, e.g., racemic or scalemic mixtures. The compounds described herein may contain one or more asymmetric centers, thus potentially giving rise to diastereomers and optical isomers. Unless stated to the contrary, the present invention includes all such possible diastereomers, as well as their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and their pharma- ceutically acceptable salts. Mixtures of stereoisomers, and isolated specific stereoisomers are also included. During the course of the synthetic procedures used to prepare such compounds, or when using racemization or epimerization procedures known to those skilled in the art, the products of such procedures may be mixtures of stereoisomers.

[0075] Many organic compounds exist in optically active forms that have the ability to rotate the plane of plane-polarized light. In describing optically active compounds, the prefixes D and L or R and S are used to indicate the absolute configuration of the molecule about its chiral center(s). The prefixes d and l, or (+) and (-), are used to indicate the sign of rotation of plane-polarized light by the compound, with (-) or l meaning that the compound is levorotatory. Compounds prefixed with (+) or d are dextrorotatory. For a given chemical structure, these compounds, called stereoisomers, are identical except that they are non-superimposable mirror images of one another. A particular stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often referred to as an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture. Many of the compounds described herein can have one or more chiral centers and therefore can exist in different enantiomeric forms. If desired, a chiral carbon can be indicated with an asterisk (*). When a bond to a chiral carbon is shown as a straight line in a disclosed formula, it is understood that both the (R) and (S) configurations of the chiral carbon, and thus both enantiomers and mixtures thereof, are encompassed within the formula. As used in the art, when it is desired to specify the absolute configuration for a chiral carbon, one of the bonds to the chiral carbon can be shown as a wedge (a bond to an atom above the plane) and the other can be shown as a row of short parallel lines or a wedge (a bond to an atom below the plane). The Cahn-Ingold-Prelog system can be used to assign the (R) or (S) configuration to a chiral carbon.

[0076] The compounds described herein can contain atoms in both their natural isotopic abundance and non-natural abundance.The disclosed compounds can be isotopically labeled or isotopically substituted compounds identical to those described, but due to the fact that one or more atoms are replaced by atoms with atomic mass or mass number different from the atomic mass or mass number typically found in nature.Exemplary isotopes that can be incorporated into the compounds of the present invention include, respectively:2 H, 3 H, 13 C. 14 C. 15 N, 18 O. 17 O. 35 S, 18 F, and 36 Included within the scope of the present invention are isotopes of hydrogen, carbon, nitrogen, oxygen, sulfur, fluorine, and chlorine, such as Cl. The compounds further include prodrugs thereof, and pharma- ceutically acceptable salts of the compounds or of the prodrugs that contain the aforementioned isotopes and / or other isotopes of other atoms. Certain isotopically labeled compounds of the present invention, such as 3 H and 14 Those in which a radioactive isotope such as C is incorporated are useful in drug and / or substrate tissue distribution assays. Tritiated, i.e., 3 H, and carbon-14, i.e. 14 C isotopes are particularly preferred for their ease of preparation and detectability. Additionally, deuterium, i.e., 2 Substitution with heavier isotopes such as H can confer certain therapeutic advantages resulting in greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements, and therefore may be preferred in some circumstances. The isotopically labeled compounds of the present invention and their prodrugs can generally be prepared by carrying out the following procedure by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.

[0077] The compounds described in the present invention may exist as solvates.In some cases, the solvent used to prepare solvates is an aqueous solution, and solvates are often called hydrates.The compounds can exist as hydrates, which can be obtained, for example, by crystallization from a solvent or from an aqueous solution.In this regard, one, two, three, or any number of solvents or water molecules can be combined with the compounds according to the present invention to form solvates and hydrates.Unless otherwise stated, the present invention includes all such possible solvates.

[0078] It is also understood that certain compounds described herein can exist in equilibrium between tautomers, for example, a ketone having an α-hydrogen can exist in equilibrium between the keto and enol forms. [ka] Similarly, amides with an N-hydrogen can exist in equilibrium between the amide form and the imidic acid form, and unless stated to the contrary, the invention includes all such possible tautomers.

[0079] Chemical substances are known to form solids that exist in different ordered states, called polymorphic forms or modifications. Different modifications of polymorphic substances can vary greatly in their physical properties. Compounds according to the present invention can exist in different polymorphic forms, and it is possible that certain modifications are metastable. Unless otherwise stated, the present invention includes all such possible polymorphic forms.

[0080] In some embodiments, the structure of the compound may be represented by the formula: [ka]

[0081] is understood to be equivalent to the formula: [ka]

[0082] In the formula, n is typically an integer. That is, R n is a group consisting of five independent substituents, R n(a) , R n(b) , R n(c) , R n(d) , and R n(e)By "independent substituents" it is meant that each R substituent can be defined independently. For example, in one example, if Rn(a) is a halogen, then R n(b) does not necessarily have to be a halogen.

[0083] As used herein, "administering" can refer to administration orally, topically, intravenously, subcutaneously, transdermally, transdermally, intramuscularly, intraarticularly, parenterally, intraarterially, intradermally, intraventricularly, intraosseously, intraocularly, intracranially, intraperitoneally, intralesionally, intranasally, intracardially, intraarticularly, intracavernosally, intrathecally, intravitreally, intracerebrally, intraventricularly, intratympanically, intracochlearly, rectally, intravaginally, by inhalation, by catheter, stent, or via implanted reservoirs or other devices that administer the composition either actively or passively (e.g., by diffusion) through perivascular spaces and adventitia. For example, a medical device such as a stent can contain a composition or formulation disposed on its surface, which can then dissolve or disperse into the surrounding tissues and cells. The term "parenteral" can include subcutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranially injection or infusion techniques. Administration can be continuous or intermittent. In various aspects, the preparations can be administered therapeutically, i.e., administered to treat an existing disease or condition. In further various aspects, the preparations can be administered prophylactically, i.e., administered for the prevention of a disease or condition.

[0084] As used interchangeably herein, a "subject," "individual," or "patient" can refer to a vertebrate organism, such as a mammal (e.g., a human). A "subject" can also refer to a cell, a population of cells, a tissue, an organ, or an organism, preferably a human and components thereof.

[0085] As used herein, the terms "treating" and "treatment" can generally refer to obtaining a desired pharmacological and / or physiological effect. The effect can be, but is not necessarily, preventative in terms of preventing or partially preventing a disease, such as hematological malignancies, breast cancer, and / or another solid malignancy, its symptoms, or conditions. The effect can be therapeutic in terms of partially or completely curing a disease, condition, symptom, or adverse effects caused by the disease, disorder, or condition. The term "treatment" as used herein can include any treatment of hematological malignancies, breast cancer, and / or another solid tumor in a subject, particularly a human, and can include any one or more of the following: (a) preventing the disease from occurring in a subject who may have a predisposition to the disease but has not yet been diagnosed as having the disease, (b) inhibiting the disease, i.e., preventing the onset of the disease, and (c) alleviating the disease, i.e., alleviating or ameliorating the disease and / or its symptoms or conditions. The term "treatment" as used herein can refer to therapeutic treatment alone, prophylactic treatment alone, or both therapeutic and prophylactic treatment. Those in need of treatment (subjects in need of treatment) can include those who already have a disorder and / or those for whom a disorder is to be prevented. As used herein, the term "treating" can include inhibiting a disease, disorder, or condition, e.g., preventing its progression, as well as alleviating a disease, disorder, or condition, e.g., causing regression of a disease, disorder, and / or condition. Treating a disease, disorder, or condition can include improving at least one symptom of a particular disease, disorder, or condition, even if the underlying pathophysiology is not affected, such as treating a subject's pain by administering an analgesic, even though such an agent does not treat the cause of the pain.

[0086] As used herein, a "therapeutic agent" can refer to treating, curing, and / or ameliorating a disease, disorder, condition, or side effect, or reducing the rate of progression of a disease, disorder, condition, or side effect.

[0087] As used herein, "effective amount" can refer to an amount of a disclosed compound or pharmaceutical composition provided herein that is sufficient to produce a beneficial or desired biological, emotional, medical, or clinical response in a cell, tissue, system, animal, or human. An effective amount can be administered in one or more administrations, applications, or dosages. The term can also include within its scope an amount effective to enhance or restore substantially normal physiological function.

[0088] For example, it is well within the skill of the art to start a dose of a compound at a level lower than that required to achieve a desired therapeutic effect, and gradually increase the dosage until the desired effect is achieved. If desired, an effective daily dose can be divided into multiple doses for administration. Consequently, a single dose composition can contain such amounts or submultiples thereof to make up a daily dose. In the event of any contraindications, the dosage can be adjusted by the individual physician. In general, it is preferred that the maximum dose of the pharmacological agent of the present invention (alone or in combination with other therapeutic agents), i.e., the highest safe dose according to sound medical judgment, is used. However, it will be understood by those skilled in the art that a patient may require a lower dose or a tolerable dose for medical reasons, psychological reasons, or virtually any other reason.

[0089] Response to a therapeutically effective dose of the disclosed compounds and / or pharmaceutical compositions can be measured by determining the physiological effect of the treatment or pharmaceutical, such as, for example, a reduction or absence of disease symptoms after administration of the treatment or pharmacological agent. Other assays for measuring the level of response are known to those skilled in the art and can be used. The amount of treatment can be varied, for example, by increasing or decreasing the amount of the disclosed compounds and / or pharmaceutical compositions, by changing the disclosed compounds and / or pharmaceutical compositions administered, by changing the route of administration, by changing the timing of administration, etc. Dosages can vary and can be administered in one or more doses per day for one or several days. Guidance can be found in the literature for appropriate dosages of a given class of pharmaceutical products.

[0090] As used herein, the term "prophylactically effective amount" refers to an amount effective to prevent the development or onset of a disease or condition.

[0091] As used herein, the term "prevent" or "preventing" refers to preventing, avoiding, eliminating, forestalling, hindering, or impeding something from happening, especially by prior action. Where reduce, inhibit, or prevent are used herein, it is understood that the use of the other two words is also expressly disclosed unless specifically indicated otherwise.

[0092] The term "pharmacologically acceptable" describes a material that is not biologically or otherwise undesirable, i.e., does not cause unacceptable levels of undesirable biological effects or interact in a deleterious manner.

[0093] The term "pharmaceutical acceptable salt" as used herein means a salt of an active principle prepared with an acid or base that is tolerated by biological systems or tolerated by subjects when administered in therapeutically effective amounts, or tolerated by biological systems and tolerated by subjects.When a compound of the present disclosure contains a relatively acidic functional group, a base addition salt can be obtained by contacting a neutral form of such a compound, either neat or in a suitable inert solvent, with a sufficient amount of the desired base.Examples of pharmaceutical acceptable base addition salts include, but are not limited to, sodium, potassium, calcium, ammonium, organic amino, magnesium salts, lithium salts, strontium salts, or similar salts.When a compound of the present disclosure contains a relatively basic functional group, an acid addition salt can be obtained by contacting a neutral form of such a compound, either neat or in a suitable inert solvent, with a sufficient amount of the desired acid. Examples of pharma- ceutically acceptable acid addition salts include, but are not limited to, those derived from inorganic acids such as hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphate, dihydrogenphosphate, sulfuric, monohydrogensulfuric, hydroiodic, or phosphorous acids, and the like, as well as salts derived from relatively non-toxic organic acids such as acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, etc. Also included are salts of amino acids, such as alginates, and salts of organic acids, such as glucuronic or galacturonic acid.

[0094] The term "pharmaceutical acceptable prodrug" or "prodrug" refers to a prodrug of a compound of the present disclosure that is suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, etc., within the scope of sound medical judgment, commensurate with a reasonable benefit / risk ratio, and effective for their intended use. The prodrugs of the present disclosure can be rapidly converted in vivo, for example, by hydrolysis in blood, to the parent compound having the structure of the disclosed compound. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, V.14 of the ACS Symposium Series, and Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press (1987).

[0095] The term "pharmaceutical acceptable vehicle" refers to a diluent, adjuvant, excipient, or carrier with which a compound of the present disclosure is administered. The term "effective amount" or "pharmaceutical effective amount" refers to a non-toxic but sufficient amount of an agent to provide a desired biological result. The result may be reduction and / or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. An appropriate "effective" amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.

[0096] "Pharmaceutically acceptable carriers" for therapeutic use are well known in the pharmaceutical art and are described, for example, in Remington's Pharmaceutical Sciences, 18th Edition (Easton, Pennsylvania: Mack Publishing Company, 1990). For example, sterile saline and phosphate-buffered saline at physiological pH may be used. Preservatives, stabilizers, dyes, and even flavoring agents may be provided in the pharmaceutical composition. For example, sodium benzoate, sorbic acid, and esters of p-hydroxybenzoic acid may be added as preservatives. Id.at1449. Additionally, antioxidants and suspending agents may be used. Id.

[0097] As used herein, the term "derivative" refers to a compound having a structure derived from that of a parent compound (e.g., a compound disclosed herein) and whose structure is sufficiently similar to that disclosed herein that it would be expected by one of skill in the art to exhibit the same or similar activity and utility as the claimed compound or to induce the same or similar activity and utility as the compound claimed as a precursor, based on that similarity. Exemplary derivatives include salts, esters, amides, salts of esters or amides, and N-oxides of the parent compound.

[0098] The term "modulating" or "modulate" refers to the treating, prevention, suppression, enhancement, or induction of a function, condition, or disorder. For example, compounds of the disclosure may modulate PDAC by inhibiting the BET protein BRD4 and the histone acetyltransferase EP300 / CBP, both of which are ubiquitously expressed in PDAC tissues and act in concert to enhance tumor development.

[0099] The term "contacting" as used herein refers to bringing a disclosed compound or pharmaceutical composition into close proximity with a cell, target protein, or other biological entity in such a manner that the disclosed compound or pharmaceutical composition can affect the activity of the cell, target protein, or other biological entity either directly, i.e., by interacting with the cell, target protein, or other biological entity itself, or indirectly, i.e., by interacting with another molecule, cofactor, factor, or protein on which the activity of the cell, target protein, or other biological entity itself depends.

[0100] As used herein, a "dose," "unit dose," or "dosage" can refer to a physically discrete unit suitable for use in a subject, each unit containing a predetermined quantity of a disclosed compound and / or pharmaceutical composition thereof calculated to produce a desired response or responses associated with its administration.

[0101] Certain of the materials, compounds, compositions, and components disclosed herein can be obtained commercially or readily synthesized using techniques generally known to those of skill in the art. For example, starting materials and reagents used in preparing the disclosed compounds and compositions are available from commercial suppliers such as Aldrich Chemical Co., (Milwaukee, Wis.), Acros Organics (Morris Plains, NJ), Fisher Scientific (Pittsburgh, Pa.), or Sigma (St. Louis, Mo.), or may be readily obtained by direct marketing in a variety of formats, including but not limited to Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991); March's Advanced Organic Chemistry (John Wiley and Sons, 4th Edition); and Larock's Comprehensive Organic Transformations (VCH Publishers, 1997). These compounds can be prepared by methods known to those skilled in the art, either according to procedures described in references such as "The Journal of Chemistry, vol. 13, no. 1, pp. 111-119, 1999" or by methods known to those skilled in the art.

[0102] Unless expressly stated otherwise, it is never intended that any method set forth herein be construed as requiring that its steps be performed in a particular order. Thus, unless a method claim actually recites the order in which its steps are to be followed or specifically states in the claims or description that the steps are to be limited to a particular order, no order is intended to be implied in any way. This holds true for any possible implicit basis for interpretation, including the obvious meaning derived from the arrangement of steps or operational flow, grammatical construction or punctuation, and logical matters regarding the number or type of embodiments described in the specification.

[0103] Disclosed are the components used to prepare the compositions of the present invention, as well as the compositions themselves used within the methods disclosed herein. These and other materials are disclosed herein, and when combinations, subsets, interactions, groups, etc. of these materials are disclosed, it is understood that specific references to the various individual and collective combinations and permutations of each of these compounds cannot be explicitly disclosed, but each is specifically contemplated and described herein. For example, when a particular compound is disclosed and discussed, and several modifications that can be made to several molecules that include that compound are discussed, each and every combination and permutation of that compound and possible modifications is specifically contemplated, unless otherwise specifically indicated to the contrary. Thus, if a class of molecules A, B, and C, as well as a class of D, E, and F, and an example of a combination molecule AD is disclosed, combinations AE, AF, BD, BE, BF, CD, CE, and CF are considered to be disclosed, each meaning individually and collectively contemplated, even if each is not individually listed. Similarly, any subset or combination of these is also disclosed. Thus, for example, the subgroups AE, BF, and CE are considered to be disclosed. This concept applies to all aspects of this application, including, but not limited to, steps in methods of making and using the compositions of the invention. Thus, where there are various additional steps that can be performed, it is understood that each of these additional steps can be performed with any particular embodiment or combination of embodiments of the methods of the invention.

[0104] It is understood that the compositions disclosed herein have certain functions. Disclosed herein are certain structural requirements for performing the disclosed functions, and it is understood that there are a variety of structures that can perform the same functions associated with the disclosed structures, and that these structures will typically achieve the same results.

[0105] As used herein, the term "optional" or "optionally" means that the event or circumstance described thereafter may or may not occur, and that the description includes instances in which the event or circumstance occurs and instances in which the event or circumstance does not occur.

[0106] Unless otherwise indicated, temperatures referred to herein are based on atmospheric pressure (ie, 1 atmosphere).

[0107] Methods for Treating Cancer Associated with Ras Mutations Described herein is a method for treating cancer associated with Ras mutation in a subject in need of treatment. Mutant RAS is a driving factor in tumor initiation and maintenance. There are three human RAS genes that code for four RAS proteins: Kirsten rat sarcoma viral oncogene homolog (KRAS), neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS), and Harvey rat sarcoma viral oncogene homolog (HRAS), with two KRAS isoforms (KRAS4A and KRAS4B) resulting from alternative RNA splicing. RAS proteins (KRAS4A, KRAS4B, NRAS, and HRAS) function as GDP-GTP-regulated binary on-off switches to regulate cytoplasmic signaling networks that control a variety of normal cellular processes.

[0108] In one embodiment, the Ras gene is at least 15%, at least 20%, or at least 30% mutated. The cancer associated with the Ras gene mutation includes lung cancer, gastrointestinal cancer, breast cancer, pancreatic cancer, colon cancer, or blood cancer. In another embodiment, the cancer associated with the Ras mutation is small intestine adenocarcinoma, rectal adenocarcinoma, bile duct cancer, gallbladder cancer, neuroblastoma, pancreatic ductal adenocarcinoma (PDAC), or melanoma.

[0109] In pancreatic ductal adenocarcinoma (PDAC), bromodomain and extraterminal motif (BET) proteins contribute to disease pathogenesis primarily through transcriptional activation of several oncogenes, including c-MYC and FOSL1. In addition, the EP300 bromodomain is essential for oncogenic cMYC expression and cell proliferation.

[0110] Thus, described herein are compounds and formulations thereof that can modulate the activity of bromodomains and bromodomain extraterminal (BET) family of bromodomain proteins for the treatment of PDAC.In one aspect, the compounds described herein inhibit EP300 and CBP (a structural analogue of EP300) proteins at bromodomain 4 (BRD4).In another aspect, the compounds described herein suppress the known action of EP300, acetylation of H3K27.

[0111] In another aspect, the compounds described herein can suppress oncogenic KRAS signaling. KRAS mutations are observed in over 90% of PDAC patients and result in permanent activation of the KRAS protein, which drives cellular processes associated with several cancers, including proliferation, transformation, invasion, and survival (41-44). Oncogenic KRAS mutations have long been regarded as early events in PDAC pathogenesis, and persistent KRAS activity is required for both initiation and maintenance of the neoplastic phenotype (45). Despite the well-established role of oncogenic KRAS in PDAC, KRAS has proven largely drug-inaccessible in the clinic (46). While most therapies directed against KRAS have attempted to directly interfere with the KRAS protein (46), the compounds described herein inhibit BRD4 and EP300, thereby preventing KRAS transcription and suppressing its downstream signaling.

[0112] The compounds described herein have improved efficacy compared to the benchmark BET inhibitor JQ-1, and efficacy comparable to high dose JQ-1. In one embodiment, the compounds are administered in combination with an effective amount of an immune checkpoint inhibitor, such as, for example, a PD-1 / PD-L1 inhibitor, a CTLA-4 inhibitor, or a combination thereof.

[0113] Pyridinone Compounds In one aspect, the compounds described herein have the formula I, [ka] During the ceremony, R 12 is C1-C3 alkyl, C1-C3 haloalkyl, propylenyl, -CH2(CO)CH=CH2, oxiran-2-ylmethyl, or CH2(CO)CH2Cl; R 11 is a nitrogen-containing bicyclic or tricyclic heteroaryl, aryl, or biaryl, each of which is optionally independently selected from -N(R a )S(O)2R b , -S(O)NR a R b , -C(O)NR a R b -N(R a )C(O)R b -NR a R b , -(C1-C6 alkylenyl)R c , -(C1-C3 cycloalkylenyl)R c , aryl, heteroaryl, -(C1-C6 alkylenyl)R c R c’ , -H, halogen, -CN, propylenyl, C1-C3 alkyl, C1-C3 haloalkyl, -OR 70 , -NR 70 R 70 , -C(O)OR 70 , -C(O)NR 70 R 70 , -S(O)2R 70, -S(O)NR 70 R 70 , -CH2(CO)CH=CH2, oxiran-2-ylmethyl, CH2(CO)CH2Cl, and R 70 and is substituted with one, two or three substituents selected from X is optionally present and, if present, is selected from the group consisting of -O-, -C(O)-, -N(R 77 )-, and -CH(R 70 )- is selected from R 77 -H, halogen, -CN, C1-C3 haloalkyl, -OR 70 , -NR 70 R 70 , -C(O)OR 70 , -C(O)NR 70 R 70 , -S(O)2R 70 , -S(O)NR 70 R 70 , and R 70 is selected from the group consisting of R 70 each occurrence independently represents C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, C1-C6 haloalkyl, -CN, NO2, -OR e , -S(O)NR e R f , -C(O)R e , -C(O)NR e R f , -NR e R f -N(R e )C(O)R f , -(C1-C6 alkylenyl)-OR e , -(C1-C6 alkylenyl)-C(O)NR e R f , -(C1-C6 alkylenyl)-NR e R f , and -(C1-C6 alkylenyl)-N(R e )C(O)R f is selected from R a and R beach occurrence independently represents H, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 haloalkyl, R c and C1-C6 alkyl, wherein the C1-C6 alkyl is optionally selected from -OR e , -NR e R f , -C(O)OR e , -C(O)NR e R f , -S(O)2R e , -S(O)NR e R f , and R c is substituted with one substituent selected from R c and R c’ is independently selected from aryl, heteroaryl, heterocycle, cycloalkyl, and cycloalkenyl, and each R c The group optionally comprises 1, 2, 3, 4, or 5 R d is substituted with a group, R d each occurrence independently represents C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, C1-C6 haloalkyl, -CN, -NO2, -OR e , -S(O)NR e R f , -C(O)R e , -C(O)NR e R f , -NR e R f , -N(R e )C(O)R f , -(C1-C6 alkylenyl)-OR e , -(C1-C6 alkylenyl)-C(O)NR e R f , -(C1-C6 alkylenyl)-NR e R f , and -(C1-C6 alkylenyl)-N(R e )C(O)R f is selected from R e and R fis independently selected from H, C1-C6 alkyl, C1-C6 cycloalkyl, aryl, heteroaryl, and C1-C6 haloalkyl at each occurrence.

[0114] In one embodiment, the compound is of formula II: [ka] During the ceremony, R1, [ka] and R2, [ka] and R3 is H or C1-C6 alkyl; R 80 is C1-C3 alkyl; X1, X2, and X3 are each independently selected from the group consisting of CH or N.

[0115] In one embodiment, R of formula II 12 is C1-C3 alkyl, such as, for example, methyl. In another embodiment, R2 of formula II is [ka] wherein X1 is N, X2 is N, and X3 is CH. In another embodiment, R3 of formula II is C1-C3 alkyl, such as, for example, methyl. In another embodiment, R1 of formula II is [ka] wherein R of formula II 80is, for example, C1-C3 alkyl such as ethyl.

[0116] In another embodiment, the compound is of formula III: [ka] In the formula, R 31 but, [ka] and R 157 is Me, CH2CH3, or CH(CH3)2, R 32 is selected from the group consisting of C1-C6 alkyl, C1-C6 alkenyl, C1-C8 cycloalkyl, -H, -D, C1-C8 substituted cycloalkylenyl, substituted aryl, and substituted heteroaryl; R 33 , R 34 , R 35 , R 36 , R 37 , R 34’ , R 35’ , R 36’ , R 37’ are each independently selected from the group consisting of -H, halogen, -CN, C1-C3 haloalkyl, C1-C6 cycloalkyl, C1-C6 alkylamine, C1-C6 cycloalkylamine, C1-C6 alkyl ester, and C1-C6 alkylamide.

[0117] In one embodiment, R of formula III 33 , R 34 , R 35 , R 36 , R 37 , R 34’ , R 35’ , R 36’ , R 37’ In another embodiment, R of formula III is 32 is C1-C3 alkyl, such as, for example, methyl. In another embodiment, R 31 teeth, [ka] where R 157 is Me, CH2CH3, or CH(CH3)2.

[0118] In another embodiment, the compound has formula IV [ka] or a pharma- ceutically acceptable salt thereof. This compound is also referred to herein as XP-524.

[0119] Exemplary methods for producing the compounds described herein are disclosed in WO2019 / 109057, which is incorporated by reference in its entirety.

[0120] Immune checkpoint inhibitors In certain embodiments, the pyridine-based compounds described herein can be co-administered with one or more immune checkpoint inhibitors.Immune checkpoint inhibitor therapy targets immune checkpoints, which are key regulators of the immune system that, when stimulated, can weaken immune response to immunological stimulation.Some cancers may protect themselves from attack by stimulating immune checkpoint targets.Checkpoint therapy can block inhibitory checkpoints and restore the function of the immune system.

[0121] In one embodiment, the immune checkpoint inhibitor includes a PD-1 inhibitor, a PD-L1 inhibitor, or a CTLA-4 inhibitor. In one embodiment, the immune checkpoint inhibitor is an antibody. In one embodiment, the PD-1 inhibitor is nivolumab (Opdivo®), pembrolizumab (Keytruda®), and cemiplimab (Libtayo®). In another embodiment, the PD-L1 inhibitor is atezolizumab (Tecentriq®), avelumab (Bavencio®), and durvalumab (Imfinzi®). In another embodiment, the CTLA-4 inhibitor is ipilimumab (Yervoy®).

[0122] In one aspect, the invention provides a method of treating PDAC, comprising: (a) administering to a subject in need of treatment an effective amount of a pyridine-based compound described herein; and (b) administering to the subject an effective amount of an immune checkpoint inhibitor. In another aspect, the administration of step (a) is prior to the administration of step (b). In another embodiment, the administration of step (a) is subsequent to the administration of step (b). In yet another embodiment, the administration of step (a) is simultaneous with the administration of step (b).

[0123] "Concurrent administration", "co-administration", "simultaneous administration", and similar phrases mean that two or more agents are administered to a subject to be treated at the same time. "Concurrently" means that each agent is administered either at the same time or sequentially in any order at different times. For example, a compound of formula I may be administered simultaneously with an immune checkpoint inhibitor or sequentially in any order at different times. A compound of formula I immune checkpoint inhibitor may be administered separately in any suitable form and by any suitable route. However, when not administered simultaneously, it is meant that they are administered to an individual sequentially and sufficiently close in time to provide the desired therapeutic effect and act in concert. When a compound of formula I and an immune checkpoint inhibitor are not administered simultaneously, it is understood that they may be administered in any order to a subject in need of a compound of formula I and an immune checkpoint inhibitor. For example, a compound of formula I can be administered to an individual in need of a compound of formula I prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks prior to), concomitantly with, or subsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) administration of an immune checkpoint inhibitor. In various embodiments, the compound of Formula I and the immune checkpoint inhibitor are administered 1 minute apart, 10 minutes apart, 30 minutes apart, less than 1 hour apart, 1 hour apart, 1 to 2 hours apart, 2 to 3 hours apart, 3 to 4 hours apart, 4 to 5 hours apart, 5 to 6 hours apart, 6 to 7 hours apart, 7 to 8 hours apart, 8 to 9 hours apart, 9 to 10 hours apart, 10 to 11 hours apart, 11 to 12 hours apart, less than 24 hours apart, or less than 48 hours apart. In one embodiment, the components of the combination therapy are administered 1 minute to 24 hours apart.

[0124] In one aspect, the pyridine-based compound and the immune checkpoint inhibitor are administered as separate unit doses, hi another aspect, the pyridine-based compound and the immune checkpoint inhibitor are formulated in a single pharmaceutical formulation with a pharma- ceutically acceptable carrier.

[0125] Pharmaceutical Compositions In various aspects, the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of at least one of the disclosed compounds, at least one of the products of the disclosed methods, or a pharma- ceutically acceptable salt thereof.As used herein, "pharma-ceutically acceptable carrier" refers to one or more of pharma-ceutically acceptable diluents, preservatives, antioxidants, solubilizers, emulsifiers, colorants, release agents, coating agents, sweeteners, flavorings, and aromatics, and adjuvants.The disclosed pharmaceutical compositions can be conveniently presented in unit dosage form and can be prepared by any of the methods well known in the art of pharmacy and pharmaceutical science.

[0126] In a further aspect, the disclosed pharmaceutical compositions comprise a therapeutically effective amount of at least one of the disclosed compounds, at least one product of the disclosed methods, or a pharma- ceutically acceptable salt thereof as an active ingredient, a pharma- ceutically acceptable carrier, optionally one or more other therapeutic agents, and optionally one or more adjuvants. The disclosed pharmaceutical compositions include those suitable for oral, rectal, topical, pulmonary, nasal, and parenteral administration, although the most suitable route in any given case will depend on the particular host and the nature and severity of the condition for which the active ingredient is being administered. In a further aspect, the disclosed pharmaceutical compositions can be formulated to allow for oral, nasal, via inhalation, parenteral, paracancer, transmucosal, transdermal, intramuscular, intravenous, intradermal, subcutaneous, intraperitoneal, intraventricular, intracranial, and intratumoral administration.

[0127] As used herein, "parenteral administration" includes administration by bolus injection or infusion, as well as administration by intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular subarachnoid, intraspinal, epidural, and intrasternal injection and infusion.

[0128] In various aspects, the present disclosure also relates to pharmaceutical compositions comprising a pharma- ceutically acceptable carrier or diluent and, as an active ingredient, a therapeutically effective amount of the disclosed compounds, products of the disclosed methods of making, pharma- ceutically acceptable salts, hydrates, solvates, polymorphs, or stereochemically isomeric forms thereof. In further aspects, the disclosed compounds, products of the disclosed methods of making, pharma- ceutically acceptable salts, hydrates, solvates, polymorphs, or stereochemically isomeric forms thereof, or any subgroups or combinations thereof, may be formulated into various pharmaceutical forms for administration purposes.

[0129] In practice, the compounds of the present disclosure, or pharma- ceutically acceptable salts thereof, may be combined as active ingredients in intimate admixture with pharmaceutical carriers by conventional pharmaceutical compounding techniques. The carriers may take a wide variety of forms, depending on the form of preparation desired, for example, for oral or parenteral (including intravenous) administration. Thus, the pharmaceutical compositions of the present disclosure may be presented as discrete units suitable for oral administration, such as capsules, cachets, or tablets, each containing a predetermined amount of the active ingredient. Furthermore, the compositions may be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion, or as a water-in-oil liquid emulsion. In addition to the common dosage forms described above, the compounds of the present disclosure and / or pharma- ceutically acceptable salt(s) thereof may also be administered by controlled release means and / or delivery devices. The compositions may be prepared by any of the methods of pharmacy. In general, such methods include the step of bringing into association the active ingredient with the carrier, which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredients with liquid carriers or finely divided solid carriers, or both, and the product can then be conveniently shaped into the desired presentation.

[0130] For ease of administration and uniformity of dosage, it is particularly advantageous to formulate the aforementioned pharmaceutical composition in unit dosage form. As used herein, the term "unit dosage form" refers to a physically separate unit suitable as a uniform dosage, each unit containing a predetermined amount of active ingredient calculated to produce a desired therapeutic effect in association with the required pharmaceutical carrier. That is, "unit dosage form" is interpreted to mean a single dose in which all active and inactive ingredients are combined in a suitable system, so that a patient, or a person who administers a drug to a patient, can open a single container or package containing the entire dose contained therein, and there is no need to mix any components together from two or more containers or packages. Typical examples of unit dosage forms are tablets (including scored or coated tablets) for oral administration, capsules or pills, single-dose vials for injectable solutions or suspensions, suppositories for rectal administration, powder packets, wafers, and segregated multiples thereof. This list of unit dosage forms is not intended to be limiting in any manner, but is merely intended to represent typical examples of unit dosage forms.

[0131] The pharmaceutical compositions disclosed herein comprise a compound of the present disclosure (or a pharma- ceutically acceptable salt thereof) as an active ingredient, a pharma- ceutically acceptable carrier, and, optionally, one or more additional therapeutic agents. In various aspects, the disclosed pharmaceutical compositions may comprise a pharma- ceutically acceptable carrier and the disclosed compound or a pharma- ceutically acceptable salt thereof. In further aspects, the disclosed compound or a pharma- ceutically acceptable salt thereof may also be included in a pharmaceutical composition in combination with one or more other therapeutically active compounds. The compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host and the nature and severity of the condition for which the active ingredient is being administered. The pharmaceutical compositions may be conveniently presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy.

[0132] Techniques and compositions for making dosage forms useful in the materials and methods described herein are described, for example, in the following references: Modern Pharmaceutics, Chapters 9 and 10 (Banker & Rhodes, Editors, 1979); Pharmaceutical Dosage Forms: Tablets (Lieberman et al., 1981); Ansel, Introduction to Pharmaceutical Dosage Forms 2nd Edition (1976); Remington's Pharmaceutical Sciences, 17th ed. (Mack Publishing Company, Easton, Pa., 1985); Advances in Pharmaceutical Sciences (David Ganderton, Trevor Jones, Eds., 1992); Advances in Pharmaceutical Sciences Vol 7. (David Ganderton, Trevor Jones, James McGinity, Eds., 1995); Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms (Drugs and the Pharmaceutical Sciences, Series 36 (James McGinity, Ed., 1989), Pharmaceutical Particulate Carriers: Therapeutic Applications: Drugs and the Pharmaceutical Sciences, Vol 61 (Alain Rolland, Ed., 1993), Drug Delivery to the Gastrointestinal Tract (Ellis Horwood Books in the Biological Sciences. Series in Pharmaceutical Technology; JGHardy, SSDavis, Clive G. Wilson, Eds.), Modern Pharmaceutics Drugs and the Pharmaceutical Sciences, Vol 40 (Gilbert S. Banker, Christopher T. Rhodes, Eds.). .

[0133] The compounds described herein are typically administered in admixture with a suitable pharmaceutical diluent, excipient, filler, or carrier (herein referred to as pharma- ceutically acceptable carrier, or carrier), which is appropriately selected for the intended form of administration and consistent with conventional pharmaceutical practice. The deliverable compound may be in a form suitable for oral, rectal, topical, intravenous injection, or parenteral administration. Carriers include solids or liquids, and the type of carrier is selected based on the type of administration used. The compound may be administered as a dosage having a known amount of the compound.

[0134] Due to ease of administration, oral administration may be the preferred dosage form, with tablets and capsules representing the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously used. However, other dosage forms may be suitable, depending on the clinical population (e.g., age and severity of clinical condition), the solubility characteristics of the particular disclosed compound used, and the like. Thus, the disclosed compounds may be used in oral dosage forms such as pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. In preparing compositions for oral dosage forms, any convenient pharmaceutical medium may be used. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like may be used to form oral liquid preparations such as suspensions, elixirs, and solutions, while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules, and tablets. Due to ease of administration, tablets and capsules are the preferred oral dosage units, whereby solid pharmaceutical carriers are used. Optionally, tablets may be coated by standard aqueous or nonaqueous techniques.

[0135] The disclosed pharmaceutical compositions in oral dosage form may include one or more pharmaceutical excipients and / or additives. Non-limiting examples of suitable excipients and additives include gelatin, natural sugars such as raw sugar or lactose, lecithin, pectin, starch (e.g., corn starch or amylose), dextran, polyvinylpyrrolidone, polyvinyl acetate, gum arabic, alginic acid, tylose, talc, lycopodium, silica gel (e.g., colloidal), cellulose, cellulose derivatives (e.g., cellulose ethers in which the cellulose hydroxyl groups are partially etherified with low-saturated aliphatic alcohols and / or low-saturated aliphatic oxyalcohols, e.g., methyloxypropylcellulose, methylcellulose, hydroxypropylmethylcellulose, phthalic acid, cellulose ethers in which the cellulose hydroxyl groups are partially etherified with ... methyloxypropylcellulose, methylcellulose, hydroxypropylmethylcellulose, phthalic acid, cellulose ethers in which the cellulose hydroxyl groups are partially etherified with low-saturated aliphatic oxyalcohols, methyloxypropylcellulose, methylcellulose, hydroxypropylmethylcellulose, methylcellulose, methylcellulose, methylcellulose, methylcellulose, methylcellulose, methylcellulose, methylcellulose, methylcellulose, methylcellulose, methylcellulose, methylcellulose, methylcellulose, methylcellulose, methylcellulose hydroxypropylmethylcellulose), fatty acids and in particular the magnesium, calcium or aluminium salts of saturated fatty acids having 12 to 22 carbon atoms (for example the stearates), emulsifiers, oils and fats, in particular vegetable (for example peanut oil, castor oil, olive oil, sesame oil, cottonseed oil, corn oil, wheat germ oil, sunflower seed oil, cod liver oil, in each case also optionally hydrated); glycerol esters and polyglycerol esters C12H24O2 to C18H36O2 of saturated fatty acids, and mixtures thereof, in which the glycerol hydroxy groups may be totally or also only partially esterified (for example mono-, di- and triglycerides);Pharmaceutically acceptable monohydric or polyhydric alcohols and polyglycols such as polyethylene glycol and derivatives thereof, monohydric aliphatic alcohols (1-20 carbon atoms) or glycols, esters of saturated or unsaturated aliphatic fatty acids (2-22 carbon atoms, especially 10-18 carbon atoms) with polyhydric alcohols such as glycerol, diethylene glycol, pentacrithritol, sorbitol, mannitol, etc., which may also be optionally etherified, esters of primary alcohols and citric acid, acetic acid, urea, benzyl benzoate, dioxolane, glyceroformal, tetrahydrofurfuryl alcohol, polyglycol ethers with C1-C12 alcohols, dimethylacetamide, lactamide, lactate, ethyl carbonate, silicones (especially medium viscosity polydimethylsiloxanes), calcium carbonate, sodium carbonate, calcium phosphate, sodium phosphate, magnesium carbonate, etc.;

[0136] Other auxiliary substances useful for the preparation of oral dosage forms are substances that cause disintegration (so-called disintegrants), such as cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch, sodium carboxymethylcellulose or microcrystalline cellulose. Conventional coating substances can also be used to produce oral dosage forms. For example, those that may be considered are polymerizates and copolymers of acrylic acid and / or methacrylic acid and / or their esters; copolymers of acrylic acid and methacrylic acid esters with a lower ammonium group content (e.g. Eudragit® RS), copolymers of acrylic acid and methacrylic acid esters, and trimethylammonium methacrylate (e.g. Eudragit® RS). RL); polyvinyl acetate; fats, oils, waxes, fatty alcohols; hydroxypropyl methylcellulose phthalate or acetate succinate; cellulose acetate phthalate, starch acetate phthalate, and polyvinyl acetate phthalate, carboxymethylcellulose; methylcellulose phthalate, methylcellulose succinate, methylcellulose phthalate succinate, and methylcellulose phthalate half ester; zein; ethylcellulose and ethylcellulose succinate; shellac, gluten; ethylcarboxylcellulose; ethacrylate-maleic anhydride copolymer; maleic anhydride-vinyl methyl ether copolymer; styrene-maleic acid copolymer; 2-ethyl-hexyl-acrylate maleic anhydride; crotonic acid-vinyl acetate copolymer; glutamic acid / glutamic acid ester copolymer; carboxymethylethylcellulose glycerol monooctanoate; cellulose acetate succinate; polyarginine.

[0137] Plasticizers that may be considered as coating materials in the disclosed oral dosage forms include citric acid and tartaric acid esters (acetyl-triethyl citrate, acetyl tributyl citrate, tributyl citrate, triethyl citrate); glycerol and glycerol esters (glycerol diacetate, glycerol triacetate, acetylated monoglycerides, castor oil); phthalic acid esters (dibutyl, diamyl, diethyl, dimethyl, dipropyl phthalate), di-(2-methoxy- or 2-ethoxyethyl)-phthalate, ethyl phthalyl glycolate, butyl phthalyl ethyl, and butyl; alkoxy esters (glycerol diacetate, glycerol triacetate, acetylated monoglycerides, castor oil); These include: ethanol (propylene glycol, polyethylene glycols of various chain lengths), adipates (diethyl adipate, di-(2-methoxy- or 2-ethoxyethyl)-adipate; benzophenone; diethyl and dibutyl sebacate, dibutyl succinate, dibutyl tartrate, diethylene glycol dipropionate; ethylene glycol diacetate, ethylene glycol dibutyrate, ethylene glycol dipropionate; tributyl phosphate, tributyrin; polyethylene glycol sorbitan monooleate (polysorbates such as Polysorbar 50); sorbitan monooleate.

[0138] Furthermore, the carrier may include suitable binder, lubricant, disintegrant, colorant, flavoring agent, flow inducer, and melting agent. The pharmaceutical carrier used may be, for example, solid, liquid, or gas. Examples of solid carrier include, but are not limited to, lactose, terra alba, sucrose, glucose, methylcellulose, dicalcium phosphate, calcium sulfate, mannitol, sorbitol talc, starch, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carrier are sugar syrup, peanut oil, olive oil, and water. Examples of gas carrier include carbon dioxide and nitrogen.

[0139] In various embodiments, binders can include, for example, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, etc. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, etc. In further embodiments, disintegrants can include, for example, starch, methylcellulose, agar, bentonite, xanthan gum, etc.

[0140] In various aspects, oral dosage forms, such as solid dosage forms, can include the disclosed compounds bound to polymers as targetable drug carriers or as prodrugs. Suitable biodegradable polymers useful for achieving controlled release of drugs include, for example, polylactic acid, polyglycolic acid, copolymers of polylactic acid and polyglycolic acid, caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyano acylates, and hydrogels, preferably covalently crosslinked hydrogels.

[0141] Tablets may contain the active ingredient in admixture with non-toxic pharma- ceutically acceptable excipients suitable for tablet manufacture.These excipients may be, for example, inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, or sodium phosphate; granulating and disintegrating agents such as corn starch or alginic acid; binders such as starch, gelatin, or acacia, and lubricants such as magnesium stearate, stearic acid, or talc.Tablets may be uncoated or may be coated by known techniques to delay disintegration and absorption in the digestive tract, thereby providing a sustained action over a longer period of time.

[0142] The tablet containing the disclosed compound can be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants.Compressed tablets can be prepared by compressing the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active agent, or dispersant, in a suitable machine.Molded tablets can be made by molding a mixture of the powdered compound moistened with an inert liquid diluent in a suitable machine.

[0143] In various embodiments, solid oral dosage forms such as tablets can be coated with an enteric coating to prevent rapid disintegration in the stomach. In various embodiments, enteric coatings include, but are not limited to, hydroxypropylmethylcellulose phthalate, methacrylic acid-methacrylic acid ester copolymer, polyacetate-vinyl phthalate, and cellulose acetate phthalate. Akihiko Hasegawa "Application of solid dispersions of Nifedipine with enteric coating agent to prepare a sustained-release dosage form" Chem. Pharm. Bull. 33: 1615-1619 (1985). Various enteric coating materials can be selected based on trials to achieve an enteric coated dosage form designed from the beginning to have a preferred combination of dissolution time, coating thickness, and diametral crushing strength (see, for example, SC Porter et al. "The Properties of Enteric Tablet Coatings Made From Polyvinyl Acetate-phthalate and Cellulose acetate Phthalate", J. Pharm. Pharmacol. 22: 42p (1970)). In further embodiments, the enteric coating can include hydroxypropyl-methylcellulose phthalate, methacrylic acid-methacrylic acid ester copolymer, polyacetate-vinyl phthalate, and cellulose acetate phthalate.

[0144] In various embodiments, the oral dosage form can be a solid dispersion with a water-soluble or water-insoluble carrier. Examples of water-soluble or water-insoluble carriers include, but are not limited to, polyethylene glycol, polyvinylpyrrolidone, hydroxypropylmethyl-cellulose, phosphatidylcholine, polyoxyethylene hydrogenated castor oil, hydroxypropylmethylcellulose phthalate, carboxymethylethylcellulose, or hydroxypropylmethylcellulose, ethylcellulose, or stearic acid.

[0145] In various aspects, oral dosage forms can be liquid dosage forms, including those that are ingested or alternatively administered as mouthwash or gargle.For example, liquid dosage forms can include aqueous suspensions containing active substances mixed with excipients suitable for the manufacture of aqueous suspensions.In addition, oily suspensions can be formulated by suspending active substances in vegetable oils, such as peanut oil, olive oil, sesame oil, or coconut oil, or mineral oils, such as liquid paraffin.Oily suspensions can also contain various excipients.The pharmaceutical compositions of the present disclosure can also be in the form of oil-in-water emulsions, which can also contain excipients, such as sweeteners and flavoring agents.

[0146] For the preparation of solutions or suspensions, it is possible to use, for example, water, in particular sterile water, or physiologically acceptable organic solvents, such as alcohols (ethanol, propanol, isopropanol, 1,2-propylene glycol, polyglycols and their derivatives, fatty alcohols, partial esters of glycerol), oils (for example peanut oil, olive oil, sesame oil, almond oil, sunflower oil, soybean oil, castor oil, bovine hoof oil), paraffin, dimethyl sulfoxide, triglycerides, etc.

[0147] In the case of liquid dosage forms, such as drinkable solutions, the following substances may be used as stabilizers or solubilizers: lower aliphatic mono- and polyhydric alcohols having 2 to 4 carbon atoms, such as ethanol, n-propanol, glycerol, polyethylene glycols having a molecular weight of 200 to 600 (e.g., 1 to 40% aqueous solution), diethylene glycol monoethyl ether, 1,2-propylene glycol, organic amides, such as amides of aliphatic C1-C6-carboxylic acids with ammonia, or primary, secondary, or tertiary C1-C4-amines, or C1-C4-hydroxyamines, such as urea, urethane, acetamide, N-methylacetamide, N,N-diethylacetamide, N,N-dimethylacetamide, lower aliphatic amines and diamines having 2 to 6 carbon atoms, such as ethylenediamine, hydroxyethyltheophylline, tromethamine (e.g., as a 0.1 to 20% aqueous solution), aliphatic amino acids.

[0148] In preparation, the disclosed liquid dosage forms may contain and use solubilizers and emulsifiers such as the following non-limiting examples: polyvinylpyrrolidone, sorbitan fatty acid esters such as sorbitan trioleate, phosphatides such as lecithin, acacia, tragacanth, polyoxyethylated sorbitan monooleate and other ethoxylated fatty acid esters of sorbitan, polyoxyethylated fats, polyoxyethylated oleotriglycerides, linoleated oleotriglycerides, polyethylene oxide condensation products of fatty alcohols, alkylphenols, or fatty acids, or also 1-methyl-3-(2-hydroxyethyl)imidazolidone-(2). In this context, polyoxyethylated means that the substance in question contains polyoxyethylene chains, the degree of polymerization of which is generally between 2 and 40, in particular between 10 and 20. Polyoxyethylated substances of this type can be obtained, for example, by reaction of hydroxyl-containing compounds (e.g., mono- or diglycerides, or unsaturated compounds such as those containing an oleic acid radical) with ethylene oxide (e.g., 40 moles of ethylene oxide per mole of glyceride). Examples of oleotriglycerides are olive oil, peanut oil, castor oil, sesame oil, cottonseed oil, corn oil. See also Dr. HP Fiedler "Lexikon der Hillsstoffe fur Pharmazie, Kostnetik und angrenzende Gebiete" 1971, pages 191-195.

[0149] In various embodiments, the liquid dosage form may further comprise preservatives, stabilizers, buffer substances, flavor correctors, sweeteners, colorants, antioxidants, complexing agents, etc. For example, complexing agents that may be considered are chelating agents such as ethylenediamine retrascetic acid, nitrilotriacetic acid, diethylenetriaminepentaacetic acid, and salts thereof.

[0150] Optionally, it may be necessary to stabilize the liquid dosage form with a physiologically acceptable base or buffer to a pH range of approximately 6 to 9. Wherever possible, neutral or slightly basic pH values ​​(maximum pH 8) will be preferred.

[0151] To enhance the solubility and / or stability of the disclosed compounds in the disclosed liquid dosage forms, parenteral injection forms, or intravenous injection forms, it may be advantageous to use α-, β-, or γ-cyclodextrin or derivatives thereof, particularly hydroxyalkyl-substituted cyclodextrins, such as 2-hydroxypropyl-β-cyclodextrin or sulfobutyl-β-cyclodextrin. Co-solvents such as alcohols may also improve the solubility and / or stability of the compounds according to the present disclosure in pharmaceutical compositions.

[0152] In various aspects, the disclosed liquid dosage forms, parenteral injection forms, or intravenous injection forms may further comprise liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes may be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.

[0153] The pharmaceutical composition of the present disclosure is suitable for injection, such as parenteral administration, such as intravenous, intramuscular, or subcutaneous administration. Pharmaceutical compositions for injection can be prepared as a solution or suspension of the active compound in water. Suitable surfactants, such as hydroxypropylcellulose, can be included. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oil. In addition, preservatives can be included to prevent harmful growth of microorganisms.

[0154] Pharmaceutical compositions of the present disclosure suitable for parenteral administration may include sterile aqueous or oily solutions, suspensions, or dispersions. Furthermore, the compositions may be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In some embodiments, the final injectable form must be sterile and effectively fluid for use in a syringe. The pharmaceutical composition should be stable under the conditions of manufacture and storage, and thus should preferably be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier may be a solvent or dispersion medium, containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.

[0155] For example, injectable solutions can be prepared in which the carrier comprises saline, glucose solution, or a mixture of saline and glucose solution. Also, injectable suspensions can be prepared, in which case appropriate liquid carriers, suspending agents, and the like can be used. In some embodiments, the disclosed parenteral formulations can include about 0.01-0.1M, e.g., about 0.05M, phosphate buffer. In further embodiments, the disclosed parenteral formulations can include about 0.9% saline.

[0156] In various aspects, the disclosed parenteral pharmaceutical compositions may include pharma- ceutically acceptable carriers, such as aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Aqueous carriers include water, alcoholic / aqueous solutions, emulsions, or suspensions, including, but not limited to, saline and buffered media. Parenteral vehicles may include mannitol, normal serum albumin, sodium chloride solution, Ringer's dextrose, dextrose, and sodium chloride, lactated Ringer's, and fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as, for example, antibacterial agents, antioxidants, collating agents, inert gases, and the like. In further aspects, the disclosed parenteral pharmaceutical compositions may contain minor amounts of additives such as substances that enhance isotonicity and chemical stability, e.g., buffers and preservatives.Also contemplated as injectable pharmaceutical compositions are solid form preparations, which are intended to be converted to liquid form preparations immediately prior to use.Furthermore, other adjuvants may be included to render the formulation isotonic with the blood of the subject or patient.

[0157] In addition to the pharmaceutical compositions described herein above, the disclosed compounds can also be formulated as depot preparations.Such long-acting preparations can be administered by implantation (e.g., subcutaneous or intramuscular) or by intramuscular injection.Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in acceptable oil) or ion exchange resins, or as poorly soluble derivatives, for example, poorly soluble salts.

[0158] The pharmaceutical compositions of the present disclosure may be in a form suitable for topical administration. As used herein, the phrase "topical application" refers to administration on a biological surface, whereby the biological surface includes, for example, skin areas (e.g., hands, forearms, elbows, legs, face, nails, anal, and genital areas) or mucous membranes. By selecting an appropriate carrier and optionally other ingredients that may be included in the composition, as described herein below, the compositions of the present disclosure may be formulated into any form typically used for topical application. Topical pharmaceutical compositions may be in the form of creams, ointments, pastes, gels, lotions, milks, suspensions, aerosols, sprays, foams, dusting powders, pads, and patches. Additionally, the compositions may be in a form suitable for use in transdermal devices. These formulations utilizing the compounds of the present disclosure or pharma- ceutically acceptable salts thereof may be prepared via conventional processing methods. As an example, a cream or ointment is prepared by mixing a hydrophilic material and water together with about 5% to about 10% by weight of the compound to produce a cream or ointment having a desired consistency.

[0159] In compositions suitable for transdermal administration, the carrier optionally comprises a penetration enhancer and / or a suitable wetting agent, optionally combined in minor proportions with suitable additives of any nature, which do not introduce significant adverse effects on the skin. Such additives may facilitate administration to the skin and / or may aid in preparing the desired composition. These compositions may be administered in various ways, for example, as a transdermal patch, as a spot-on, as an ointment.

[0160] Ointments are semi-solid preparations typically based on petrolatum or petroleum derivatives. The particular ointment base used is one that provides optimal delivery of the active agent selected for a given formulation, and preferably provides other desirable characteristics (e.g., emulsification) as well. As with other carriers or vehicles, ointment bases should be inert, stable, non-irritating, and non-sensitizing. As explained in Remington: The Science and Practice of Pharmacy, 19th Ed., Easton, Pa.: Mack Publishing Co. (1995), pp. 1399-1404, ointment bases can be divided into four classes: oleaginous bases, emulsifiable bases, emulsion bases, and water-soluble bases. Oleaginous ointment bases include, for example, vegetable oils, fats obtained from animals, and semi-solid hydrocarbons obtained from petroleum. Emulsifiable ointment bases, also known as absorbent ointment bases, contain little or no water and include, for example, hydroxystearin sulfate, anhydrous lanolin, and hydrophilic petrolatum. Emulsion ointment bases are either water-in-oil (W / O) emulsions or oil-in-water (O / W) emulsions and include, for example, cetyl alcohol, glyceryl monostearate, lanolin, and stearic acid. Preferred water-soluble ointment bases are prepared from polyethylene glycols of varying molecular weight.

[0161] Lotions are preparations that are applied to the skin surface without friction. Lotions are typically liquid or semi-liquid preparations in which solid particles, including active agents, are present in a water or alcohol base. Due to the ease of applying a more fluid composition, lotions are typically preferred for treating large body areas. Lotions are typically suspensions of solids, often including liquid oily emulsions of the oil-in-water type. In general, it is necessary to finely divide the insoluble materials in lotions. Lotions typically contain suspending agents to create better dispersion, as well as compounds such as methylcellulose, sodium carboxymethylcellulose, etc., that are useful for placing and holding the active agent in contact with the skin.

[0162] Creams are viscous liquids or semisolid emulsions, either oil-in-water or water-in-oil. Cream bases are typically water-washable and contain an oil phase, an emulsifier, and an aqueous phase. The oil phase, also called the "internal" phase, is generally composed of petrolatum and / or fatty alcohols, such as cetyl or stearyl alcohol. The aqueous phase typically, although not necessarily, exceeds the oil phase in volume and generally contains a moisturizer. The emulsifier in a cream formulation is generally a nonionic, anionic, cationic, or amphoteric surfactant. For further information, reference may be made to Remington: The Science and Practice of Pharmacy, supra.

[0163] Pastes are semi-solid dosage forms in which bioactive agents are suspended in a suitable base. Depending on the nature of the base, pastes are divided into fatty pastes or pastes made from single-phase aqueous gels. The base in fatty pastes is generally petrolatum, hydrophilic petrolatum, etc. Pastes made from single-phase aqueous gels generally incorporate carboxymethylcellulose, etc. as a base. For additional information, Remington: The Science and Practice of Pharmacy can be referred to.

[0164] Gel formulations are semi-solid suspension-type systems. Single-phase gels contain organic macromolecules that are distributed substantially uniformly throughout the carrier liquid, which is typically aqueous, but preferably also contains alcohol and optionally oil. Preferred organic macromolecules, i.e., gelling agents, are crosslinked acrylic acid polymers, e.g., carboxypolyalkylenes, such as the family of carbomer polymers that can be obtained commercially under the trademark Carbopol. Other types of preferred polymers in this context are hydrophilic polymers, such as polyethylene oxide, polyoxyethylene-polyoxypropylene copolymers, and polyvinyl alcohol; modified celluloses, such as hydroxypropylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose phthalate, and methylcellulose; gums, such as tragacanth and xanthan gum; sodium alginate; and gelatin. To prepare a homogeneous gel, dispersing agents, such as alcohol or glycerin, can be added, or the gelling agent can be dispersed by trituration, mechanical mixing or stirring, or a combination thereof.

[0165] Sprays generally provide the active agent in an aqueous and / or alcoholic solution that can be misted onto the skin for delivery. Such sprays include those formulated to provide a concentrate of the active agent solution at the site of administration after delivery, for example, the spray solution may be composed primarily of alcohol or other similar volatile liquids that can dissolve the active agent. Once delivered to the skin, the carrier evaporates, leaving a concentrated active agent at the site of administration.

[0166] Foam compositions are typically formulated in single or multi-phase liquid form and are optionally housed in a suitable container with a propellant that facilitates the composition's discharge from the container, thus converting the composition into a foam upon application. Other foam-forming techniques include, for example, the "bag-in-a-can" formulation technique. Compositions formulated in this way typically contain low-boiling point hydrocarbons, such as isopropane. Application and stirring of such compositions at body temperature causes the isopropane to evaporate in a manner similar to pressurized aerosol foaming systems, producing foam. Foams can be water-based or aqueous alkanol, but are typically formulated with a high alcohol content, which evaporates quickly upon application to the user's skin, driving the active ingredient through the upper skin layers to the treatment site.

[0167] The skin patch typically comprises a backing material to which a reservoir containing an active agent is attached. The reservoir can be, for example, a pad in which the active agent or composition is dispersed or soaked, or a liquid reservoir. The patch typically further comprises a front water-permeable adhesive, which adheres and fixes the device to the treatment area. Silicone rubber with self-adhesive properties can alternatively be used. In either case, a protective permeable layer can be used to protect the adhesive side of the patch before use. The skin patch can further comprise a removable cover, which serves to protect the skin patch during storage.

[0168] Examples of patch configurations that can be utilized with the present invention include single-layer or multi-layer drug-in-adhesive systems, characterized by the inclusion of drug directly in the adhesive that contacts the skin.In such transdermal patch designs, the adhesive not only serves to attach the patch to the skin, but also serves as a formulation base that contains the drug and all excipients under a single backing film.In multi-layer drug-in-adhesive patches, a membrane is placed between two separate drug-in-adhesive layers, or multiple drug-in-adhesive layers are incorporated under a single backing film.

[0169] Examples of pharma- ceutically acceptable carriers suitable for topical pharmaceutical compositions include carrier materials well known for use in the cosmetic and medical fields as bases for, for example, emulsions, creams, aqueous solutions, oils, ointments, pastes, gels, lotions, milks, foams, suspensions, aerosols, etc., depending on the final form of the composition. Thus, representative examples of suitable carriers according to the present invention include, but are not limited to, water, liquid alcohols, liquid glycols, liquid polyalkylene glycols, liquid esters, liquid amides, liquid protein hydrolysates, liquid alkylated protein hydrolysates, liquid lanolin and lanolin derivatives, and similar materials commonly used in cosmetic and medicinal compositions. Other suitable carriers according to the present invention include, but are not limited to, alcohols such as monohydric and polyhydric alcohols, e.g., ethanol, isopropanol, glycerol, sorbitol, 2-methoxyethanol, diethylene glycol, ethylene glycol, hexylene glycol, mannitol, and propylene glycol; ethers such as diethyl or dipropyl ether; polyethylene glycol and methoxypolyoxyethylene (carbowaxes having molecular weights ranging from 200 to 20,000); polyoxyethylene glycerol, polyoxyethylene sorbitol, stearoyl diacetin, and the like.

[0170] The topical composition of the present disclosure may be presented in a pack or dispenser device, such as a kit approved by the FDA, which may contain one or more unit dosage forms containing active ingredients, if desired. The dispenser device may, for example, comprise a tube. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser device may also be accompanied by a notice in a form prescribed by a government agency regulating the manufacture, use, or sale of pharmaceuticals, which notice reflects the agency's approval of the composition form for human or veterinary administration. Such notice may include, for example, a label approved by the U.S. Food and Drug Administration for prescription drugs or an approved product insert. Also, a composition comprising the topical composition of the present invention formulated in a pharmaceutically acceptable carrier may be prepared, placed in a suitable container, and labeled for the treatment of the indicated condition.

[0171] Another patch system configuration that can be used according to the present invention is a reservoir transdermal system design, characterized by including a liquid compartment containing a drug solution or suspension separated from a release liner by a semipermeable membrane and an adhesive. The adhesive component of this patch system can be incorporated either as a continuous layer between the membrane and the release liner or in a concentric configuration around the membrane. Yet another patch system configuration that can be utilized according to the present invention is a matrix-based design, characterized by including a semisolid matrix containing the drug solution or suspension in direct contact with the release liner. The components responsible for skin adhesion are incorporated in a superimposed manner, forming a concentric configuration around the semisolid matrix.

[0172] The pharmaceutical composition of the present disclosure may be in a form suitable for rectal administration, in which the carrier is solid.Preferably, the mixture forms unit-dose suppositories.Suitable carriers include cocoa butter and other materials commonly used in the art.Suppositories can be conveniently formed by first mixing the composition with softened or melted carrier(s), followed by cooling and shaping in molds.

[0173] Pharmaceutical compositions containing the compounds of the present disclosure and / or pharma- ceutically acceptable salts thereof may also be prepared in powder or liquid concentrate form.

[0174] The pharmaceutical composition (or formulation) may be packaged in a variety of ways. Generally, for distribution, the article includes a container that contains the pharmaceutical composition in an appropriate form. Suitable containers are well known to those skilled in the art and include materials such as bottles (plastic and glass), sachets, foil blister packs, etc. The container may also include a tamper-evident assembly to prevent inadvertent access to the contents of the package. In addition, the container is typically disposed with a label describing the contents of the container and any appropriate warnings or instructions.

[0175] The disclosed pharmaceutical compositions may be presented in a pack or dispenser device, which may contain one or more unit dosage forms containing the active ingredient, if desired. The pack, such as a blister pack, may contain, for example, metal or plastic foil. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also bear a notice associated with the container in a format prescribed by a government agency regulating the manufacture, use, or sale of pharmaceuticals, which notice reflects the approval by the agency of the form of the drug for human or veterinary administration. Such notice may be, for example, a label approved by the U.S. Food and Drug Administration for prescription drugs, or an approved product insert. Also, pharmaceutical compositions containing the disclosed compounds formulated in a compatible pharmaceutical carrier may be prepared, placed in a suitable container, and labeled for the treatment of an indicated condition.

[0176] The exact dosage and frequency of administration will depend, as is well known to those skilled in the art, on the particular disclosed compound, the product of the disclosed method of making, its pharma- ceutically acceptable salt, solvate, or polymorph, hydrate, solvate, polymorph, or stereochemically isomeric form thereof, the particular condition being treated, and the severity of the condition being treated; various factors specific to the medical history of the subject to whom the dosage is administered, such as age; weight, sex, degree of disability, and general health of the particular subject, as well as other medications that the individual may be taking. Furthermore, it will be apparent that the effective daily amount may be lowered or increased depending on the response of the subject being treated and / or depending on the evaluation of the physician prescribing the compound of the present disclosure.

[0177] The disclosed pharmaceutical compositions may further comprise other therapeutically active compounds, which are usually applied in the treatment of the above mentioned pathological or clinical conditions.

[0178] It is understood that the disclosed compositions can be prepared from the disclosed compounds. It is also understood that the disclosed compositions can be used in the disclosed methods of use.

[0179] As already mentioned, the present disclosure relates to pharmaceutical compositions comprising a therapeutically effective amount of the disclosed compounds, the products of the disclosed methods of making, pharma- ceutically acceptable salts, hydrates, solvates, polymorphs, and a pharma- ceutically acceptable carrier. In addition, the present disclosure relates to a process for preparing such pharmaceutical compositions, characterized in that a pharma- ceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound according to the present disclosure.

[0180] Methods of using pyridinone compounds and formulations thereof Any amount of pyridinone compound and optional immune checkpoint inhibitor described herein may be administered to a subject in need of the pyridinone compound and optional immune checkpoint inhibitor one or more times per day, week, month, or year. In some aspects, the amount administered is an effective amount of pyridinone compound(s) and optional immune checkpoint inhibitor. For example, the pyridinone compound may be administered in a total daily dose. The total daily dose may be given in a single dose per day. In other aspects, the total daily dose may be administered over multiple doses per day, with each dose containing a portion of the total daily dose (partial dose) administered. In some aspects, the amount of doses delivered per day may be 2, 3, 4, 5, 6, or more. In further aspects, the pyridinone compound and optional immune checkpoint inhibitor may be administered to a subject one or more times per week, such as 1, 2, 3, 4, 5, or 6 times per week. In other aspects, the pyridinone compound and optional immune checkpoint inhibitor may be administered to a subject one or more times per month, such as 1, 2, 3, 4-5 or more times per month. In still further aspects, the pyridinone compound and optional immune checkpoint inhibitor may be administered to a subject one or more times per year, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10-11 or more times per year.

[0181] In some embodiments, the pyridinone compounds and optional immune checkpoint inhibitors may be used as co-therapy or combination therapy with one or more other co-active agents or treatment modalities. In some embodiments, the pyridinone compounds and optional immune checkpoint inhibitors may be administered simultaneously, contemporaneously, and / or sequentially with conventional chemotherapeutic agents or pharmaceutical formulations thereof, radiation, and / or other cancer treatment modalities.

[0182] The amount of pyridinone compound and optional immune checkpoint inhibitor described herein may be administered in an amount ranging from about 0.001 mg to about 1000 mg per day, calculated as free or non-chlorinated compound. In some embodiments, the amount of pyridinone compound and optional immune checkpoint inhibitor may be in the range of 0.001 mg / kg to 1000 mg / kg of body weight. In some embodiments, the amount of pyridinone compound and optional immune checkpoint inhibitor may be about 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 50 to about 100 mg / kg of body weight. In some embodiments, the amount administered is an effective amount when considered as a single dose or as a sum of partial doses.

[0183] The pyridinone-based compounds and optional immune checkpoint inhibitors may be administered in combination with or include one or more other adjuncts or therapeutic compounds, as discussed elsewhere herein. Suitable adjuncts include, but are not limited to, antisense or RNA interference molecules, chemotherapeutic agents, anti-neoplastic agents, hormonal agents, antibiotics, antiviral agents, immunomodulatory agents, anti-nausea agents, pain-regulating compounds (such as opiates), anti-inflammatory agents, antipyretics, antibiotics, and / or antibodies or fragments thereof. The compound(s), and / or formulation(s), and / or additional therapeutic agent(s) may be administered simultaneously or sequentially in separate or combined pharmaceutical formulations by any convenient route. The additional therapeutic agents may be provided in their optically pure form or in their pharma-ceutically acceptable salts.

[0184] kit The pyridinone compounds described herein and optional immune checkpoint inhibitors may be presented as a combination kit. As used herein, the term "combination kit" or "kit of parts" refers to any of the compounds described herein, their derivatives, or pharmaceutical formulations, as well as any additional components used to package, sell, market, deliver, and / or administer the combination of elements contained therein or a single element such as the primary active ingredient. Such additional components include, but are not limited to, packaging materials, syringes, blister packages, bottles, and the like. When one or more of the components (e.g., active agents) contained within the kit are administered simultaneously, the combination kit may contain the active agents in a single pharmaceutical formulation (e.g., tablet) or in separate pharmaceutical formulations.

[0185] When the agents are not administered simultaneously, the combination kit may contain each agent in a separate pharmaceutical formulation. The separate pharmaceutical formulations may be contained in a single package or in separate packages within the kit.

[0186] In some embodiments, the combination kit also includes instructions printed on or contained in a tangible medium. The instructions can provide information regarding the content of the compound or pharmaceutical formulation contained therein, safety information regarding the content of the compound(s) or pharmaceutical formulation(s) contained therein, dosage of the compound(s) and / or pharmaceutical formulation contained therein, indications for use, and / or recommended treatment regime(s). In some embodiments, the instructions provide instructions for administering the compound, pharmaceutical formulation, or salt thereof to a subject in need thereof. The subject in need thereof may have or be suspected of having cancer or other disease, and histone modifications may be modulated to treat and / or prevent disease and / or symptoms thereof, which may include, but are not limited to, arthritis, lupus, pulmonary arterial hypertension, cardiac remodeling, and / or neurodegenerative disease.

[0187] In some embodiments, the kit may include one or more co-active agents in addition to the pyridinone compound, its derivative, or pharmaceutical formulation thereof. In some embodiments, the co-active agent is a conventional chemotherapeutic agent or a pharmaceutical formulation thereof. Chemotherapeutic agents include busulfan, improsulfan, piposulfan, benzodepa, carboquone, meturedepa, uredepa, altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, trimethylolmelamine, chlorambucil, chlornaphazine, cyclophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichiin, phenesterine, protease inhibitor, rifampicin ... Ledonimustine, trofosfamide, uracil mustard, carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, aclacinomycin, actinomycin F(1), anthramycin, azaserine, bleomycin, cactinomycin, carubicin, carzinophilin, chromomycin, dactinomycin, daunorubicin, daunoma isin, 6-diazo-5-oxo-1-norleucine, doxorubicin, epirubicin, mitomycin C, mycophenolic acid, nogalamycin, olivomycin, peplomycin, plicamycin, porfiromycin, puromycin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, denopterin, methotrexate, pteropterin, trimetrexate, fludarabine, 6-mercaptopurine, thiamine Amiprine, thioguanine, ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, fluororacil, tegafur, L-asparaginase, pulmozyme, aceglatone, aldophosphamide glycoside, aminolevulinic acid, amsacrine, bestrabucil, bisantrene, carboplatin, cisplatin,Defofamide, demecolcine, diaziquone, elfornithine, elliptinium acetate, etoglucide, etoposide, flutamide, gallium nitrate, hydroxyurea, interferon-alpha, interferon-beta, interferon-gamma, interleukin-2, lentinan, lonidamine, mitoguazone, mitoxantrone, mopidamol, nitracrine, pentostatin, phenamet, pirarubicin, podophyllic acid, 2-ethylhydrazide, procarbazine, razoxane, sizofiran, spirogermanium, paclitaxel, tamoxifen, teniposide, tenuazonic acid, triaziquone, 2,2',2''-trichlorotriethylamine, urethane, vinblastine, vincristine, vindesine, and combinations thereof.

[0188] Having now described aspects of the present disclosure, the following examples generally describe some additional aspects of the present disclosure. Aspects of the present disclosure are described in conjunction with the following examples and corresponding text and figures, but there is no intent to limit the aspects of the present disclosure to this description. On the contrary, the intent is to cover all alternatives, modifications, and equivalents that are included within the spirit and scope of the present disclosure.

[0189] Aspects Aspect 1. A method of treating a cancer associated with a Ras mutation in a subject in need of treatment, comprising administering to the subject an effective amount of a compound of formula I or a pharma- ceutically acceptable salt thereof; [ka] During the ceremony, R 12 is C1-C3 alkyl, C1-C3 haloalkyl, propylenyl, -CH2(CO)CH=CH2, oxiran-2-ylmethyl, or CH2(CO)CH2Cl; R 11is a nitrogen-containing bicyclic or tricyclic heteroaryl, aryl, or biaryl, each of which is optionally independently selected from -N(R a )S(O)2R b , -S(O)NR a R b , -C(O)NR a R b -N(R a )C(O)R b -NR a R b , -(C1-C6 alkylenyl)R c , -(C1-C3 cycloalkylenyl)R c , aryl, heteroaryl, -(C1-C6 alkylenyl)R c R c’ , -H, halogen, -CN, propylenyl, C1-C3 alkyl, C1-C3 haloalkyl, -OR 70 , -NR 70 R 70 , -C(O)OR 70 , -C(O)NR 70 R 70 , -S(O)2R 70 , -S(O)NR 70 R 70 , -CH2(CO)CH=CH2, oxiran-2-ylmethyl, CH2(CO)CH2Cl, and R 70 and is substituted with one, two or three substituents selected from X is optionally present and, if present, is selected from the group consisting of -O-, -C(O)-, -N(R 77 )-, and -CH(R 70 )- is selected from R 77 -H, halogen, -CN, C1-C3 haloalkyl, -OR 70 , -NR 70 R 70 , -C(O)OR 70 , -C(O)NR 70 R 70 , -S(O)2R 70 , -S(O)NR 70 R 70 , and R 70 is selected from the group consisting of R 70each occurrence independently represents C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, C1-C6 haloalkyl, -CN, NO2, -OR e , -S(O)NR e R f , -C(O)R e , -C(O)NR e R f , -NR e R f -N(R e )C(O)R f , -(C1-C6 alkylenyl)-OR e , -(C1-C6 alkylenyl)-C(O)NR e R f , -(C1-C6 alkylenyl)-NR e R f , and -(C1-C6 alkylenyl)-N(R e )C(O)R f is selected from R a and R b each occurrence independently represents H, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 haloalkyl, R c and C1-C6 alkyl, wherein the C1-C6 alkyl is optionally selected from -OR e , -NR e R f , -C(O)OR e , -C(O)NR e R f , -S(O)2R e , -S(O)NR e R f , and R c is substituted with one substituent selected from R c and R c’ is independently selected from aryl, heteroaryl, heterocycle, cycloalkyl, and cycloalkenyl, and each R c The group optionally comprises 1, 2, 3, 4, or 5 R d is substituted with a group, R deach occurrence independently represents C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, C1-C6 haloalkyl, -CN, -NO2, -OR e , -S(O)NR e R f , -C(O)R e , -C(O)NR e R f , -NR e R f , -N(R e )C(O)R f , -(C1-C6 alkylenyl)-OR e , -(C1-C6 alkylenyl)-C(O)NR e R f , -(C1-C6 alkylenyl)-NR e R f , and -(C1-C6 alkylenyl)-N(R e )C(O)R f is selected from R e and R f is independently selected from H, C1-C6 alkyl, C1-C6 cycloalkyl, aryl, heteroaryl, and C1-C6 haloalkyl at each occurrence. Aspect 2. The compound is of formula II, [ka] During the ceremony, R1, [ka] and R2, [ka] and R3 is H or C1-C6 alkyl; R 80 is C1-C3 alkyl; The method of embodiment 1, wherein X1, X2, and X3 are each independently selected from the group consisting of CH or N. Aspect 3.R 12 is C1-C3 alkyl. Aspect 4.R 12 The method of any one of aspects 1 to 3, wherein is methyl. Aspect 5. The method of any one of aspects 2 to 4, wherein R2 is: [ka] Embodiment 6. The method of embodiment 5, wherein X1 is N, X2 is N, and X3 is CH. Embodiment 7. The method of any one of embodiments 2 to 6, wherein R3 is C1-C3 alkyl. Embodiment 8. The method of any one of embodiments 2 to 6, wherein R3 is methyl. Aspect 9. The method of any one of aspects 2 to 8, wherein R1 is: [ka] Aspect 10.R 80 is ethyl. Embodiment 11. The compound is of formula III, [ka] In the formula, R 31 but, [ka] and R 157 is Me, CH2CH3, or CH(CH3)2, R 32is selected from the group consisting of C1-C6 alkyl, C1-C6 alkenyl, C1-C8 cycloalkyl, -H, -D, C1-C8 substituted cycloalkylenyl, substituted aryl, and substituted heteroaryl; R 33 , R 34 , R 35 , R 36 , R 37 , R 34’ , R 35’ , R 36’ , R 37’ is each independently selected from the group consisting of -H, halogen, -CN, C1-C3 haloalkyl, C1-C6 cycloalkyl, C1-C6 alkylamine, C1-C6 cycloalkylamine, C1-C6 alkyl ester, and C1-C6 alkylamide. Aspect 12.R 33 , R 34 , R 35 , R 36 , R 37 , R 34’ , R 35’ , R 36’ , R 37’ and each is hydrogen. Aspect 13.R 32 is C1-C3 alkyl. Aspect 14.R 32 is methyl. Aspect 15.R 31 but, [ka] where R 157 The method of any one of aspects 11-14, wherein is Me, CH2CH3, or CH(CH3)2. Aspect 16 The method of aspect 1, wherein the compound is of formula IV or a pharma- ceutically acceptable salt thereof. [ka] Embodiment 17. The method of any one of embodiments 1 to 16, further comprising administering to the subject an effective amount of an immune checkpoint inhibitor. Embodiment 18 The method of embodiment 17, wherein the immune checkpoint inhibitor comprises a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, or a combination thereof. Aspect 19. The method of aspect 17 or 18, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody. Aspect 20. The method of aspect 17, wherein the immune checkpoint inhibitor comprises nivolumab, pembrolizumab, cemiplimab, atezolizumab, avelumab, durvalumab, or any combination thereof. Embodiment 21 The method of any one of embodiments 17 to 20, wherein an immune checkpoint inhibitor is administered prior to administration of the compound. Embodiment 22 The method of any one of embodiments 17 to 20, wherein an immune checkpoint inhibitor is administered after administration of the compound. Embodiment 23 The method of any one of embodiments 17 to 20, wherein the immune checkpoint inhibitor is administered simultaneously with the administration of the compound. Aspect 24. The method of any one of aspects 1 to 23, wherein the cancer associated with a Ras mutation is lung cancer, gastrointestinal cancer, breast cancer, pancreatic cancer, colon cancer, or blood cancer. Embodiment 25. The method according to any one of embodiments 1 to 23, wherein the cancer associated with a Ras mutation is small intestine adenocarcinoma, rectal adenocarcinoma, bile duct carcinoma, gallbladder carcinoma, neuroblastoma, or melanoma. Embodiment 26 The method according to any one of embodiments 1 to 23, wherein the cancer associated with a Ras mutation is pancreatic ductal adenocarcinoma. 27. A pharmaceutical composition comprising: (a) A compound of formula I, or a pharma- ceutically acceptable salt thereof, [ka] During the ceremony, R 12is C1-C3 alkyl, C1-C3 haloalkyl, propylenyl, -CH2(CO)CH=CH2, oxiran-2-ylmethyl, or CH2(CO)CH2Cl; R 11 is a nitrogen-containing bicyclic or tricyclic heteroaryl, aryl, or biaryl, each of which is optionally independently selected from -N(R a )S(O)2R b , -S(O)NR a R b , -C(O)NR a R b -N(R a )C(O)R b -NR a R b , -(C1-C6 alkylenyl)R c , -(C1-C3 cycloalkylenyl)R c , aryl, heteroaryl, -(C1-C6 alkylenyl)R c R c’ , -H, halogen, -CN, propylenyl, C1-C3 alkyl, C1-C3 haloalkyl, -OR 70 , -NR 70 R 70 , -C(O)OR 70 , -C(O)NR 70 R 70 , -S(O)2R 70 , -S(O)NR 70 R 70 , -CH2(CO)CH=CH2, oxiran-2-ylmethyl, CH2(CO)CH2Cl, and R 70 and is substituted with one, two or three substituents selected from X is optionally present and, if present, is selected from the group consisting of -O-, -C(O)-, -N(R 77 )-, and -CH(R 70 )- is selected from R 77 -H, halogen, -CN, C1-C3 haloalkyl, -OR 70 , -NR 70 R 70 , -C(O)OR 70 , -C(O)NR 70 R 70 , -S(O)2R70 , -S(O)NR 70 R 70 , and R 70 is selected from the group consisting of R 70 each occurrence independently represents C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, C1-C6 haloalkyl, -CN, NO2, -OR e , -S(O)NR e R f , -C(O)R e , -C(O)NR e R f , -NR e R f -N(R e )C(O)R f , -(C1-C6 alkylenyl)-OR e , -(C1-C6 alkylenyl)-C(O)NR e R f , -(C1-C6 alkylenyl)-NR e R f , and -(C1-C6 alkylenyl)-N(R e )C(O)R f is selected from R a and R b each occurrence independently represents H, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 haloalkyl, R c and C1-C6 alkyl, wherein the C1-C6 alkyl is optionally selected from -OR e , -NR e R f , -C(O)OR e , -C(O)NR e R f , -S(O)2R e , -S(O)NR e R f , and R c is substituted with one substituent selected from R c and R c’ is independently selected from aryl, heteroaryl, heterocycle, cycloalkyl, and cycloalkenyl, and each R cThe group optionally comprises 1, 2, 3, 4, or 5 R d is substituted with a group, R d each occurrence independently represents C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, C1-C6 haloalkyl, -CN, -NO2, -OR e , -S(O)NR e R f , -C(O)R e , -C(O)NR e R f , -NR e R f , -N(R e )C(O)R f , -(C1-C6 alkylenyl)-OR e , -(C1-C6 alkylenyl)-C(O)NR e R f , -(C1-C6 alkylenyl)-NR e R f , and -(C1-C6 alkylenyl)-N(R e )C(O)R f is selected from R e and R f is independently selected from H, C1-C6 alkyl, C1-C6 cycloalkyl, aryl, heteroaryl, and C1-C6 haloalkyl, or a pharma- ceutically acceptable salt thereof; (b) an immune checkpoint inhibitor; (c) a pharma- ceutically acceptable carrier. 28. A kit comprising: (a) a compound of formula I, or a pharma- ceutically acceptable salt thereof, [ka] During the ceremony, R 12 is C1-C3 alkyl, C1-C3 haloalkyl, propylenyl, -CH2(CO)CH=CH2, oxiran-2-ylmethyl, or CH2(CO)CH2Cl; R11 is a nitrogen-containing bicyclic or tricyclic heteroaryl, aryl, or biaryl, each of which is optionally independently selected from -N(R a )S(O)2R b , -S(O)NR a R b , -C(O)NR a R b -N(R a )C(O)R b -NR a R b , -(C1-C6 alkylenyl)R c , -(C1-C3 cycloalkylenyl)R c , aryl, heteroaryl, -(C1-C6 alkylenyl)R c R c’ , -H, halogen, -CN, propylenyl, C1-C3 alkyl, C1-C3 haloalkyl, -OR 70 , -NR 70 R 70 , -C(O)OR 70 , -C(O)NR 70 R 70 , -S(O)2R 70 , -S(O)NR 70 R 70 , -CH2(CO)CH=CH2, oxiran-2-ylmethyl, CH2(CO)CH2Cl, and R 70 and is substituted with one, two or three substituents selected from X is optionally present and, if present, is selected from the group consisting of -O-, -C(O)-, -N(R 77 )-, and -CH(R 70 )- is selected from R 77 -H, halogen, -CN, C1-C3 haloalkyl, -OR 70 , -NR 70 R 70 , -C(O)OR 70 , -C(O)NR 70 R 70 , -S(O)2R 70 , -S(O)NR 70 R 70 , and R 70 is selected from the group consisting of R70 each occurrence independently represents C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, C1-C6 haloalkyl, -CN, NO2, -OR e , -S(O)NR e R f , -C(O)R e , -C(O)NR e R f , -NR e R f -N(R e )C(O)R f , -(C1-C6 alkylenyl)-OR e , -(C1-C6 alkylenyl)-C(O)NR e R f , -(C1-C6 alkylenyl)-NR e R f , and -(C1-C6 alkylenyl)-N(R e )C(O)R f is selected from R a and R b each occurrence independently represents H, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 haloalkyl, R c and C1-C6 alkyl, wherein the C1-C6 alkyl is optionally selected from -OR e , -NR e R f , -C(O)OR e , -C(O)NR e R f , -S(O)2R e , -S(O)NR e R f , and R c is substituted with one substituent selected from R c and R c’ is independently selected from aryl, heteroaryl, heterocycle, cycloalkyl, and cycloalkenyl, and each R c The group optionally comprises 1, 2, 3, 4, or 5 R d is substituted with a group, R deach occurrence independently represents C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, C1-C6 haloalkyl, -CN, -NO2, -OR e , -S(O)NR e R f , -C(O)R e , -C(O)NR e R f , -NR e R f , -N(R e )C(O)R f , -(C1-C6 alkylenyl)-OR e , -(C1-C6 alkylenyl)-C(O)NR e R f , -(C1-C6 alkylenyl)-NR e R f , and -(C1-C6 alkylenyl)-N(R e )C(O)R f is selected from R e and R f is independently selected from H, C1-C6 alkyl, C1-C6 cycloalkyl, aryl, heteroaryl, and C1-C6 haloalkyl, or a pharma- ceutically acceptable salt thereof; (b) an immune checkpoint inhibitor; (c) a kit comprising the compound and instructions for administering the immune checkpoint inhibitor. EXAMPLES

[0190] The following examples are set forth to provide those of ordinary skill in the art with a complete disclosure and description of how the compounds, compositions, articles, devices, and / or methods claimed herein are made and evaluated, and are intended to be purely illustrative of the disclosure and are not intended to limit the scope of what the inventors regard as their disclosure. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperatures, etc.), but some errors and deviations should be accounted for. Unless otherwise indicated, parts are parts by weight, temperature is in °C or is ambient temperature, and pressure.

[0191] Materials and Methods Cell culture and viability assays Human pancreatic cancer cells (Panc1 and MiaPaCa2) and mouse pancreatic cancer cells (KPC105) were cultured in DMEM supplemented with 10% heat-inactivated FBS, penicillin (100 U / mL), and streptomycin (100 mg / mL). ASPC1 cells were grown in RPMI1640 supplemented with 10% heat-inactivated FBS, penicillin (100 U / mL), and streptomycin (100 mg / mL). Capan1 cells were grown in IMDM1 supplemented with 10% heat-inactivated FBS, penicillin (100 U / mL), and streptomycin (100 mg / mL). Human cancer cell lines were purchased from ATCC, used within 6 months, and maintained for no more than 10 passages. KPC105 cells were used as described in a previous study (25). All cell lines in the laboratory were tested for mycoplasma every 6 months via the LookOut Mycoplasma PCR Detection Kit (Sigma Aldrich) and used only if negative.

[0192] For cell growth assays, a fixed number of serum-starved tumor cells were seeded into each well of a 24-well plate to reach 10% confluence, and the subsequent percent confluence was assessed every 4 hours until the control group reached 100% confluence. For cell viability assays, 2,000–4,000 cells in serum-free DMEM were seeded into each well of a 96-well plate. After 16 hours, medium / drugs were added and cells were cultured for 72 hours. At this point, 20 ul of 5 mg / ml 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) solution was added to each well (1:100). After 2 hours, the medium was aspirated, the crystals were dissolved in DMSO, and the absorbance at 570 nm was determined by a plate reader.

[0193] Chemicals and Reagents XP-524 was designed and synthesized as previously described (23). JQ-1 and SGC-CBP30 were purchased from Sigma Aldrich (St. Louis, MO) and reconstituted in sterile PBS at a stock concentration of 10 μM immediately before use.

[0194] BROMOscan bromodomain profiling BROMOscan bromodomain profiling was provided by DiscoverX Corp. (Fremont, Calif.) Kd of test compounds with DNA-tagged bromodomains was determined through binding to a proprietary reference immobilized ligand.

[0195] Protein crystallization Crystals of BRD4 and CBP bromodomain complexed with XP-524 were grown by hanging drop vapor diffusion at 4 °C. Prior to crystallization, 16 mg / mL of BRD4 or CBP bromodomain was incubated with 2 mM XP-524 on ice for 60 min and then centrifuged to remove precipitate. Crystals of the complexes were grown by mixing 2 μL of BRD4:XP-524 or CBP:XP-524 with 1-2 μL of reservoir solution containing 17-19% PEG3350 and 0.2 M lithium citrate tribasic tetrahydrate (pH 8.4).

[0196] Data collection and structure refinement BRD4:XP-524 crystals were generated and analyzed as previously described (23). For CBP, crystals were cryopreserved by soaking in mother liquor containing 10–15% glycerol and 200 μM XP-524, then flash frozen. Data were collected at the Life Sciences Collaborative Access Team 21-ID-F beamline at the Advanced Photon Source, Argonne National Laboratory. Data were indexed, integrated, and scaled using XDS (74), and phased first by Phaser (75) and molecular replacement using the CBP bromodomain structure (PDB entry: 5KTU) as a search model. The asymmetric unit of two CBP:XP-524 "tetramers" was then generated using an assembly of four CBP:XP-524 monomers found by Phaser as a search model by Molrep (76). Rigid-body refinement, followed by iterative rounds of restrained refinement and model building were performed using CCP4i (77) modules Refmac5 (78) and Coot (79). Coordinates and structure factors are deposited under the PDB accession code 7JUO.

[0197] antibody All antibodies were purchased from established vendors and were manufacturer verified for the specific species and applications used in this document.

[0198] RNA sequencing and gene set enrichment analysis (GSEA) Panc1 cells were treated with either DMSO vehicle, 1 μM JQ-1, JQ-1 and SGC-CBP30, or XP-524. After 24 h, RNA was extracted using the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Quality control, sequencing, and data analysis were performed by Novogene.

[0199] qPCR Quantitative gene expression was performed using gene-specific TaqMan probes, TaqMan Universal PCR Master Mix, and the 7500 Fast Real-time PCR System from Applied Biosystems (Foster City, CA). These data were quantified for relative gene expression using the comparative CT method as described in a previous study (70).

[0200] Western blot and immunoprecipitation Cell or tissue lysates were lysed in RIPA buffer (Cell Signaling) followed by sonication. Equal amounts of protein (15–50 μg) were mixed with loading dye, boiled for 8 min, separated on 4–20% denaturing SDS-PAGE gels, and transferred to PVDF membranes. Membranes were blocked for 1 h in 5% milk / TBS / 0.1% Tween and incubated with antibodies against pRB, pMEK1, MEK1, pERK1 / 2, ERK1 / 2, (Cell Signaling, Danvers, MA), H3K27ac (Active Motif, Carlsbad, CA), KRAS (Novus Bio, Saint Charles, MO), BRD4, EP300 (abcam, Cambridge, MA), or GAPDH (Santa Cruz Biotech, Santa Cruz, CA). Membranes were washed with TBS-0.1% Tween and then incubated with HRP-conjugated secondary antibodies (Cell Signaling) for 1 h at room temperature and washed again. Protein bands were visualized by enhanced chemiluminescence (Thermo Fischer, Waltham, MA) and digitally analyzed according to the manufacturer's specifications.

[0201] For immunoprecipitation, cell lysates were collected using IP buffer (25 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1% NP-40, and 5% glycerol) containing a protease and phosphatase inhibitor cocktail (Cell Signaling), and cell extracts were incubated with the respective antibodies overnight, followed by incubation with protein A or G agarose beads for 4 h at 4 °C. After 5–7 washes with lysis buffer, immune complexes were analyzed using SDS-PAGE and visualized by Western blot. All antibodies were compared to isotype-specific IgG controls to confirm specificity. All experiments were performed in triplicate unless otherwise indicated.

[0202] Transgenic mice Nongenic B6 (wild type), P48-Cre×LSL-Kras G12D (KC), Pdx1-Cre × LSL-Kras G12D ×LSL-TP53 R172H+ / - (KPC), and Pdx1-Cre × LSL-Kras G12D ×LSL-TP53 R172H+ / +KPPC mice were generated as previously described (24). Eight-week-old KC mice were administered intraperitoneal (IP) injections of either PBS vehicle or daily XP-524 (5 mg / kg). Mice were euthanized at 6 months of age, and tissues were collected for analysis. For studies involving KPC mice, animals were enrolled at 15 weeks of age, at which point they received IP injections of PBS vehicle, XP-524 (5 mg / kg), anti-PD-1, or XP-524 and anti-PD-1 as described in the text. KPC mice were sacrificed when moribund or showed clear signs of declining health, e.g., hair loss, weight loss, or lethargy, or at a fixed endpoint indicated by days after enrollment in non-survival studies. For studies involving KPPC mice, animals were enrolled either when they developed palpable tumors of 0.5 cm or at 4 weeks of age. At this time, mice were administered intraperitoneal injections (IP) of either PBS vehicle or daily XP-524 (5 mg / kg) and sacrificed when moribund or showed clear signs of declining health as described above. For euthanasia, animals were firmly anesthetized with isoflurane until they were unresponsive to paw tapping and / or gasping was observed. Thoracotomy was performed as the primary method of euthanasia, with exsanguination as a secondary method. For all mouse studies, mice were matched within 2 weeks and randomized in a 50:50 ratio of males and females.

[0203] Primary cell line derived xenografts G-68 primary cell line-derived xenografts were generated as previously described (25). Tumor size was measured twice weekly using digital calipers as described (25). Mice were euthanized when moribund, at the maximum tumor size allowed by institutional policy (2 cm), or when tumors ulcerated. For euthanasia, animals were sacrificed by CO2 asphyxiation followed by cervical dislocation, after which tumors were harvested and processed as described above.

[0204] PDAC slice culture Punch biopsies of approximately 6 mm in diameter from human PDAC tumors were sectioned into 250 μm thick slices using a Leica VT1000S vibrating blade microtome according to previously published protocols (29, 30). Slices were then placed on top of collagen-coated 0.4 μm pore membrane inserts and arranged in 6-well plates. The next day, slice cultures were treated with the indicated doses of different drugs. Fresh treatment medium was replaced every 2–3 days. At the end of the experiment, slices were fixed in 4% PFA and processed by the Pathology Core at Northwestern University. The embedded tissues were then embedded and sectioned for staining according to the protocol above.

[0205] Histology, immunohistochemistry, and immunofluorescence Mice were euthanized and pancreas, colon, lung, small intestine, liver, and spleen were subjected to pathological examination. Tissues were fixed in 10% formalin, paraffin embedded, and sections were cut at 4 mm intervals from each tissue and stained with hematoxylin and eosin (H&E), trichrome (Sigma Aldrich), or via immunohistochemistry (IHC) or immunofluorescence (IF). For immunohistochemistry, slides were deparaffinized by xylene, rehydrated through an ethanol gradient, and then heated in a pressure cooker using DAKO collection buffer (DAKO, Santa Clara, CA). Endogenous peroxidase was quenched in 3% hydrogen peroxide in methanol for 30 min. Tissues were blocked with 0.5% BSA in PBS for 30 min and stained with 1:50–1:200 for BRD4, EP300 / CBP, CD45, CD8 (abcam), RAS, IF ... G12D (Genetex, Irvine, CA), pERK, or cleaved caspase 3 (Cell Signaling, Danvers, MA). Slides were constructed using HRP-conjugated secondary antibodies followed by DAB substrate / buffer (DAKO).

[0206] For immunofluorescence, slides were heated in DAKO recovery buffer via a pressure cooker and tissues were blocked in 0.5% BSA in PBS at room temperature for 1 h. Sections were exposed to primary antibodies against CK19 (University of Iowa Hybridoma Bank), E-cadherin (Cell Signaling), PCNA, CD3, (Santa Cruz Biotechnology, Dallas, TX), or Granzyme B (Abcam, Cambridge, MA) at 1:50–1:200 overnight at 4°C. Slides were constructed using AlexaFluor 488- or 594-conjugated secondary antibodies (1:200–1:1,000, Abcam), mounted in DAPI-containing medium (Santa Cruz Biotechnology), and exposed to DAPI, FITC, and Texas Red filters.

[0207] Microscopy All images were acquired using a Nikon 40x-400x Epi-Fluorescent Inverted Microscope equipped with a Phase Contrast Kit and a Nikon brightfield camera attachment. A negative slide was used as white balance, and no analog or digital gain was used for all images. For fluorescent imaging, a positive control slide was used for each experiment, and slides were auto-exposed using Nikon NIS elements software using a gain setting of zero. The background was reduced based on the negative control slide, with the gain set to zero as well, using a LUT. These LUT values ​​and exposure times were normalized and used for all other similarly stained slides. Images were also overlaid using Nikon NIS elements software.

[0208] Tissue Slide Counts and Measurements All counts were performed by a minimum of three blinded investigators, and presentation of each value includes the average of at least three high-power fields per specimen, as described in previous publications. Score distributions were visualized via Minitab express software, with the median shown as a solid line and all individual values ​​excluding statistical outliers.

[0209] Flow cytometry Spleens were isolated, disrupted, washed with cold PBS, and the contents were filtered. For tumor specimens, samples were digested with Collagenase IV / DNase for 1 h at 37°C, mechanically dissociated, and filtered at 100 μm. Two million cells were seeded in round-bottom 96-well plates, washed with PBS, incubated with Golgi Plug / Protein Trafficking Inhibitor (BD biosciences, San Jose, CA), and stained with anti-CD45-FITC, anti-CD11b-APC, anti-CD206-PerCP / Cy5.5, anti-GR-1-APC / Cy7 (BioLegend, San Diego, CA), anti-CD4-APC / Cy7, anti-CD25-PE, Ant-CD8A-PerCP / Cy5.5 (BD biosciences), anti-CD69-APC, anti-FoxP3-FITC (eBiosciences, San Diego, CA), anti-CD4-APC-Cy7, CD25-PE (BD biosciences) at 1:200–1:1500 in PBS, as well as the Alive / Dead kit (Invitrogen, Grand Island, NY) for 30 min on ice. Cells were then fixed with 1% PFA in PBS for 10 min at room temperature and stained with anti-perforin-APC (Thermo Fischer) and anti-interferon-γ-PE (BioLegend) at 1:500–150 in perm / stain buffer (BD biosciences) for 30 min on ice and washed three times with perm / wash buffer (BD biosciences) as a panel to assess cytotoxic T cells. Analyses were performed similarly using the same gating parameters and instrumentation, and a minimum of three mice were included in each arm of the analysis. Cells were analyzed on a BD Fortessa Cytometer and exclusively gated on cells within acceptable FSC / SSC parameters. Unless otherwise stated, all subsequent flow plots correspond to live single cells based on Live / Dead assay and SSC-W gating and represent 100,000 events. High and low populations were identified based on the geometric mean of control groups based on unstained and isotype controls for each antibody. All other experiments were compared to both unstained single cells and to isotype controls.

[0210] Genome database analysis The Badea et al. and Pei et al. cohorts of PDAC patients were downloaded and visualized using the Oncomine platform. Detailed information on these datasets and DNA / RNA sequencing analyses and protocols can be found on the data portal webpages listed above. All mRNA expression values ​​are plotted on a logarithmic scale unless otherwise stated.

[0211] Authentication of sensitive resources Tail biopsy was then performed, followed by transfection with all relevant transgenes (Pdx1-Cre, P48-Cre, LSL-Kras G12D , LSL-TP53 R172H All mouse genotypes were verified by PCR for . The anti-PD-1 antibody RMP1-14 was verified by Western blot by the manufacturer (BioXcell) for its ability to recognize purified mouse PD-1 and has been used successfully to neutralize PD-1 signaling in mouse pancreatic ductal adenocarcinoma (24, 83). Validation of the compound XP-524 is described in the manuscript as well as in the original publication describing its synthesis (23).

[0212] statistical analysis Data were analyzed by either Student's T-test, simple linear regression analysis, hazard ratio, or ANOVA fitting to a general linear model in Minitab express, and their validity was tested by adherence to normality assumptions and fitted plots of residuals. Results were adjusted by Tukey's method and considered significant at p<0.05 unless otherwise stated. Results are presented either as box plots showing median and all other values ​​placed in quartiles, or as mean + standard deviation. For RNA sequencing data, significance was determined using false discovery rate (FDR) adjusted P-values, and data were considered significant at p<0.05.

[0213] result BRD4 and EP300 / CBP are ubiquitously expressed in PDAC. To determine the potential of multispecific BRD4 / EP300 inhibitors in PDAC, we first assessed the expression of both proteins in a cohort of human PDAC resection biopsies (N=14) and adjacent non-malignant tissues (N=9). In addition to increased staining intensity, PDAC tissues showed a relatively increased percentage of nuclei positive for both BRD4 and EP300 / CBP when compared to adjacent non-malignant specimens (Fig. 1A,B). Similarly, mRNA expression of both BRD4 and EP300 was increased in PDAC tumor specimens when compared to adjacent non-malignant tissues in two publicly available genomic datasets (Fig. 1C,D). BRD4 and EP300 / CBP are ubiquitously expressed in PDAC cell lines (Fig. 1E) and, with the exception of nuclear expression of BRD4, showed a similar nuclear localization pattern in Panc1 cells, as well as combined nuclear and cytoplasmic expression of EP300 / CBP (Fig. 1F).

[0214] We assessed the expression of BRD4 and EP300 / CBP in the pancreas of an increasingly aggressive mouse model of PDAC by immunohistochemistry. G12D / + In the KC model, a modest increase in the nuclear accumulation of BRD4 and EP300 / CBP was observed, which was mainly localized in developing pancreatic epithelial neoplasms (PanINs). G12D / + ×LSL-TP53 R172H+ / - (KPC) model and the Pdx1-Cre × LSL-Kras model of extremely aggressive PDAC G12D / + ×LSL-TP53 R172H+ / + Stronger and uniform nuclear expression of both proteins was found in tumor tissues from the KPPC model and the G-68 primary cell line-derived xenograft (CDX) model (Figure 1G).

[0215] XP-524 is a potent, multispecific BET inhibitor that engages BRD4 and EP300 / CBP. Given the conserved expression patterns of BRD4 and EP300 / CBP in PDAC tissues, we next explored the potential of the novel compound XP-524 (23) as a dual-specific inhibitor targeting the bromodomains of BRD4 and EP300 / CBP (Figure 2A). Compared to the prototypic benchmark BET inhibitor JQ-1, this compound showed superior potency by TR-FRET assay: XP-524 IC50 = 5.8 nM (BRD4-BD1) 1.5 nM (BRD4-BD2), JQ-1 IC50 = 200 nM (BRD4-BD1) 114 nM (BRD4-BD2). (Figure 2B,C) Further analysis via an alternative BROMOscan assay confirmed that XP-524 tightly binds and inhibits EP300 and CBP proteins with IC50s of 28 nM and 116 nM, respectively (Figure 2D).

[0216] To verify the binding of XP-524 to its target proteins and to explain the observed multispecificity, we obtained co-crystal structures of XP-524 in complex with the bromodomains of BRD4 and the EP300 homolog CBP (CBP offers favorable solubility characteristics over EP300 for co-crystallization). Similarly, XP-524 was found to orient itself in both the BRD4-BD1 and CBP bromodomains and make extensive contacts in the acetylated lysine pocket (Figure 2E). The pyrrolopyridone group of XP-524 forms a bidentate hydrogen-bonding interaction with Asn-1168 in the CBP bromodomain, and the sulfate moiety inserts itself into the ZA loop and forms a hydrogen bond with the backbone of Asp1116. The indole scaffold fits snugly into the LPF shelf through hydrophobic interactions (Figure 2F).

[0217] Superimposition of the XP-524-CBP complex with the XP-524-BRD4 complex showed a similar binding mode. Because CBP lacks a Trp for pi-pi interaction in the LPF pocket, the bottom pyridine ring of the CBP complex rotates 90°. However, XP-524 forms a cation-pi interaction with Arg1173, a key interaction in the design of potent EP300 / CBP inhibitors (26-28). In contrast, the chlorophenyl ring of JQ-1 clashes with Arg-1173, so JQ-1 is unable to capture this important cation-pi interaction, thereby blocking the binding of JQ-1 to CBP and the ability of JQ-1 to function as an EP300 / CBP inhibitor (Figure 2G).

[0218] XP-524 disrupts oncogenic KRAS signaling in vitro and ex vivo To explore the potential utility of the XP-524 compound in pancreatic cancer cells, we first incubated equal numbers of Panc1 tumor cells with either DMSO vehicle, 1 μM JQ-1, 1 μM EP300 / CBP inhibitor SGC-CBP30, JQ-1 and SGC-CBP30, 1 μM XP-524, or XP-524 and SGC-CBP30, and monitored cell growth kinetics until DMSO-treated cells reached 100% confluence. JQ-1 produced a mild growth inhibition that was significantly enhanced by the addition of SGC-CBP30, whereas SGC-CBP30 had only a minor effect on cell growth without JQ-1 (Figures 3A and S2A). In contrast, XP-524 was highly effective in suppressing tumor cell growth, closely resembling the combined effect of JQ-1 and SGC-CBP30. Consistent with its role as an EP300 / CBP inhibitor, the effect of XP-524 was not further enhanced by the addition of SGC-CBP30 (Fig. 2A ).

[0219] After repeating this experiment using MiaPaCa2 and ASPC1 cells (Fig. S2B,C), Panc1 cells were then incubated with increasing concentrations of either JQ-1 or XP-524, with or without a fixed dose of 1 μM SGC-CBP30. After 48 h, changes in cell viability were examined via MTT assay. Similar to the effects observed on cell growth, the reduction in cell viability by JQ-1 was enhanced by the addition of SGC-CBP30, significantly reducing the observed IC50. The combination of JQ-1 and SGC-CBP30 had a similar maximal efficacy as XP-524, but XP-524 was more effective at lower concentrations and was also unaffected by the addition of SGC-CBP30 (Fig. 3B and S2D).

[0220] To identify the cellular mechanisms underlying these changes, Panc1 tumor cells were then incubated with either DMSO vehicle, JQ-1, JQ-1 and SGC-CBP30, or XP-524. After 24 hours, cells were subjected to RNA sequencing (Fig. 3C). Post hoc gene set enrichment analysis suggested that XP-524 most significantly suppressed oncogenic KRAS signaling and several associated cellular processes, including MAPK pathway and cell cycle progression (Fig. 3D, E). JQ-1 led to a mild suppression of KRAS and cell cycle pathways, which was less than the effect observed using XP-524, but was improved by the addition of SGC-CBP30 (Fig. 3D, E). Given the suggested effect of XP-524 on KRAS mRNA by RNA sequencing, Panc1 cells were then treated as described and KRAS expression was assessed by qPCR after 6 hours. This confirmed a highly significant reduction in KRAS transcription following treatment with XP-524 (FIG. 3F), which was also observed using MiaPaCa2 and ASPC1 cells (FIG. 3G,H).

[0221] Panc1 cells were then re-treated with JQ-1, JQ-1 and SGC-CBP30, or XP-524, and changes in protein expression were assessed by Western blot. JQ-1 and JQ-1 / SGC-CBP30 modestly reduced the co-precipitation of BRD4 and EP300 / CBP compared to controls, which was nearly absent in cells incubated with XP-524 (Figure 3I). This was associated with a significant reduction in KRAS expression after XP-524 treatment, as well as MEK / ERK activation, paralleled by a reduction in phosphorylated RB. Interestingly, JQ-1 treatment appeared to cause a compensatory increase in histone acetylation, using H3K27ac as a surrogate marker, which was ameliorated by the addition of SGC-CBP30 and was not observed in XP-524-treated cells (Figure 3J). Using these same lysates, we also assessed the association between BRD4 and EP300 / CBP by immunoprecipitation. We next repeated this experiment using the primary KPC-105 mouse PDAC cell line, which also showed significant XP-524-induced suppression of KRAS expression and inhibition of downstream MEK / ERK activation, and observed similar results with respect to RB phosphorylation and H3K27 acetylation (Figure 3K).In a shorter experiment, XP-524 led to a similar reduction in KRAS protein expression and downstream MEK / ERK activation in MiaPaCa2 and ASPC1 cells (Figure 3L).

[0222] Next, given the inherent limitations of 2D cell cultures, we established primary PDAC slice cultures (Figure 3M) by extracting 6 mm cores from resection specimens from three patients, sectioning the cores at 250 μm intervals, and culturing them ex vivo as described (29, 30). Slice cultures were incubated with either DMSO vehicle or XP-524 (5 μM) and assessed 72 h later by immunohistochemistry. Consistent with the in vitro data (Figure 3J), XP-524 significantly reduced ERK activation in human PDAC slice cultures, as well as cell proliferation in CK19+ tumor epithelial cells (Figure 3N-P).

[0223] XP-524 reduces mutant KRAS-induced PanIN formation in vivo Given the effect of XP-524 on perturbing oncogenic KRAS signaling in vitro, we next sought to determine whether XP-524 similarly suppresses KRAS-mediated oncogenesis in vivo. Thus, we investigated the effect of XP-524 on perturbing oncogenic KRAS signaling in vitro, a well-established pathway in neoplastic disease, Ptf1a-Cre × LSL-Kras signaling. G12D We used the KC model, which serves as a reliable representative of early cancer development that develops pancreatic intraepithelial neoplasia (PanIN) by 8 weeks and typically does not progress to invasive cancer (31, 32). This is well represented in the colony, where KC mice are maintained entirely on a C57 / B6 background and develop focal areas of PanIN disease by 8 weeks with 100% penetrance, and continue to develop PanIN disease throughout the pancreas with less than 5% of mice developing focal PDAC at 1 year of age.

[0224] Using these mice, we first performed a chemoprevention study in which 8-week-old KC animals were randomized into one of two treatment groups in a 50:50 male-to-female ratio. Mice were administered daily IP injections of either PBS vehicle or 5 mg / kg XP-524 and sacrificed at fixed time points at 6 months (Figure 4A). Tissues were collected at the study endpoint, and mice treated with XP-524 showed consistent reductions in pancreatic weight, especially when normalized to total body weight (Figure 4B). On histological evaluation, XP-524-treated mice showed significant reductions in lesion burden and fibrosis, as well as increased preservation of normal acinar tissue (Figure 4C,D). Similar to the results in the cell culture system, XP-524-treated mice had substantially reduced expression of mutant RAS protein by IHC, paralleling reduced ERK activation and cell proliferation (Figure 4E,F). This was also observed by Western blotting, where XP-524-treated mice had a consistent reduction in KRAS expression as well as downstream activation of MEK / ERK signaling (FIG. 4G).

[0225] XP-524 extends survival and inhibits KRAS signaling in mouse PDAC To explore the efficacy of XP-524 in advanced disease, we next utilized two transgenic models of pancreatic cancer development. The first model was the Pdx1-Cre × LSL-Kras transgenic model of invasive PDAC. G12D ×LSL-TP53 R172H+ / - The KPC mouse colony is a pediatric colony-specific PDAC (KPC) model. This model faithfully recapitulates human PDAC histology and has several key features including poor immunogenicity and dense reactive tumor stroma. KPC animals have been reported to initially develop precursor pancreatic intraepithelial neoplasia (PanIN) at 6 weeks, focal PDAC lesions at 15 weeks, and advanced PDAC at 18 weeks (33), although this may vary depending on the individual colony and background strain. KPC mice from the colony are maintained entirely on a C57 / B6 background, with a median survival of 124 days (N=30), and develop focal areas of PDAC at a median age of 13 weeks (25).

[0226] These mice were used to initially perform an early intervention study, allowing mice to develop significant PDAC for a minimum of 15 weeks, at which point 100% of the mice in the colony developed localized PDAC. At this point, mice were then randomized into one of two treatment groups in a 50:50 male to female ratio (N=7 / group). Mice were administered daily IP injections of either PBS vehicle or 5 mg / kg XP-524, and sacrificed when they showed clear signs of decline in health, such as weight loss, ascites, or lethargy (Figure 5A). Interestingly, XP-524 significantly delayed death in KPC mice, extending median survival from 43 days to 108 days after enrollment (Figure 5B). Tissues were collected at study endpoints, sectioned, and stained for pERK with either H&E, trichrome, or immunohistochemistry. Consistent with the in vitro results, XP-524-treated mice had substantially reduced ERK activation in parallel with reduced cell proliferation and a consistent increase in apoptosis (FIGS. 5C, D).

[0227] Next, we used the Pdx1-Cre × LSL-Kras gene to treat extremely aggressive PDAC. G12D ×LSL-TP53 R172H+ / +A late intervention study was performed using the KPPC model. Colony KPPC mice have a median survival of 43 days (N=12) and develop extensive PDAC as early as 2 weeks of age. Thus, mice were enrolled either when they developed 0.5 cm tumors or at 4 weeks of age and placed into one of two treatment groups (N=6 / group). As previously described, mice were administered daily IP injections of either PBS vehicle or 5 mg / kg XP-524 and sacrificed when they showed clear signs of declining health, e.g., weight loss, ascites, or lethargy (Figure 5E). As in KPC mice, XP-524 delayed death in KPPC mice, extending median survival from 23 to 50 days after enrollment (Figure 5F). At the study endpoint, tissues were stained either with H&E or by immunohistochemistry, which revealed a gradual reduction in tumor stroma and a significant decrease in ERK activation, followed by an increase in apoptosis (Figure 5G,H).

[0228] XP-524 enhances T cell recruitment but does not promote functional antitumor immune responses Beyond the changes described for mitosis and ERK activation, substantial changes in tumor architecture were also observed after treatment with XP-524. Compared to the KPC control group, XP-524-treated tumors had a highly cellular stroma characterized by a consistent increase in lymphocytic infiltration, the majority of which stained positive for the T cell marker CD3 and was restricted to the tumor margins (Figure 6A). However, these T cells were mostly positive for the T cell exhaustion marker PD-1, and XP-524-treated tumors stained negatively for a surrogate marker for cytotoxic granzyme B (Figures 6B and S3A). To better assess immune infiltration, we repeated the in vivo study, enrolling KPC mice as described and treating them for a fixed 2-month period. At the study endpoint, pancreases and spleens were harvested from PBS- and XP-524-treated mice (N=4 / group) and subjected to flow cytometry.

[0229] Consistent with previous histopathology, tumors from XP-524-treated mice showed a significant increase in infiltration of both CD4+ and CD8+ T cells (Figure 6C), although no significant differences were observed in the spleen (Figure S3B). However, compared to positive controls, these intratumoral CD8+ T cells were negative for the activation surrogate IFNγ (Figure 6D), and both CD4+ and CD8+ T cells were mostly positive for PD-1 (Figure 6E). Interestingly, XP-524-treated mice had a significant reduction in the relative abundance of intratumoral CD4+CD25+FoxP3+ regulatory T cells (Tregs) (Figure 6F), although this was not observed in the spleen (Figure S3B). Mice treated with XP-524 did not have a consistent increase in CD45+CD11b+GR-1+ macrophage infiltration, although a modest decrease in the expression of the M2 surrogate CD206 was observed (Figure S3C).

[0230] To further explore the mechanism of XP-524-associated changes in tumor immunogenicity, we revisited our previous RNA sequencing data in Panc1 cells to explore cellular processes related to immune cell processes. Using this approach, we found that XP-524 led to upregulation of antigen processing / presentation pathways (Figure 6G) and significantly increased mRNA expression of diverse human leukocyte antigen (HLA) molecules (Figure 6H). This was also observed in vivo, where XP-524-treated mice showed increased surface staining for MHC class 1 (Figure 6I). RNA sequencing data also identified a significant suppression of the transforming growth factor β (TGFβ) pathway (Figure 6J,K). Accordingly, we assessed the concentration of TGFβ1 by ELISA and found that XP-524-treated KPC mice showed reduced intratumoral and serum levels of TGFβ1 (Figure 6L), also consistent with reduced peripheral immune tolerance.

[0231] XP-524 synergizes with PD-1 blockade to further extend survival in KPC mice Given the enhanced infiltration of functionally exhausted T cells in XP-524-treated KPC mice, as well as the observation that XP-524 increases antigen presentation and reduces immunosuppressive TGFβ signaling, we next explored the combination of XP-524 with anti-PD-1 in vivo. Again, KPC mice were allowed to develop significant PDAC for a minimum of 14 weeks and randomized into one of two treatment groups in a 50:50 male to female ratio (N=7 / group). Mice were administered either a fixed dose of 200 μg anti-PD-1 every other day and / or daily IP injections of 5 mg / kg XP-524 (Figure 7A). Anti-PD-1 had no significant effect on survival, but the combination of XP-524 and anti-PD-1 significantly improved survival, exceeding that observed with XP-524 alone. In contrast to the median survival of 51 days observed with anti-PD-1 alone, mice treated with both XP-524 and anti-PD-1 had a median survival of 161 days after enrollment (Figure 7B). Tissues were harvested again at study endpoint and revealed a robust CD45+ infiltrate in parallel with increased CD3+ T cells (Figure 7C-E). In addition, a highly significant increase in CD8+ T cells and deposition of granzyme B in residual areas of disease were observed, accompanied by increased apoptosis (Figure 7F).

[0232] We then repeated this experiment, enrolling KPC mice as described and treating them with either anti-PD-1 or XP-524 and anti-PD-1 for 2 months. At study endpoint, pancreases and spleens from anti-PD-1 or XP-524 treated mice (N=4 / group) were subjected to flow cytometry as described above. Anti-PD-1 modestly increased the presence of tumor-infiltrating T cells, but mice treated with both drugs had enhanced infiltration of CD4+ and CD8+ T cells that well exceeded that induced by XP-524 alone (Figure 7G). However, unlike T cells from mice treated with XP-524 alone, CD8+ T cells were mostly positive for IFNγ, and both the CD4+ and CD8+ populations had low levels of the exhaustion marker PD-1 (Figure 7H,I). Like XP-524 monotherapy, KPC mice treated with XP-524 and anti-PD-1 had reduced frequencies of intratumoral Tregs, CD4+CD25+FoxP3+ regulatory Tregs, and no change in splenic Tregs (Figs. 7J and S4A). Combination of XP-524 and anti-PD-1 led to a substantial increase in tumor infiltration of CD45+CD11b+GR-1+ macrophages, but reduced the proportion of macrophages positive for the M2 marker CD206 (Fig. S4B).

[0233] Consistent with increased cell-mediated cytotoxicity and reduced T cell exhaustion, the combination of XP-524 and anti-PD-1 enhanced expression of a surrogate marker for cytotoxic perforin-1 in tumor-infiltrating CD8+ T cells, but no significant changes were observed in splenic CD8+ T cells (Figure 7K). These perforin-1-expressing CD8+ T cells were also highly positive for the activation marker IFNγ, confirming reduced peripheral immune tolerance and increased antitumor immune function after treatment with XP-524 and anti-PD-1 (Figure 7L).

[0234] It should be emphasized that the above-described embodiments of the present disclosure are merely possible examples of implementations described for a clear understanding of the principles of the present disclosure. Many variations and modifications can be made to the above-described embodiment(s) without substantially departing from the spirit and principles of the present disclosure. All such modifications and variations are intended to be included within the scope of the present disclosure herein and protected by the following claims. References 1. E. Hessmann, SA Johnsen, JTSiveke, V. Ellenrieder, Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?Gut 66, 168-179 (2017). 2. A. Stathis, F. Bertoni, BET Proteins as Targets for Anticancer Treatment. Cancer Discov 8, 24-36 (2018). 3.V.Sahai,AJRedig,KACollier,FDEckerdt,HGMunshi,Targeting BET bromodomain proteins in solid tumors.Oncotarget 7,53997-54009(2016). 4.PKMazur et al., Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.Nat Med 21, 1163-1171 (2015). 5.V.Sahai et al.,BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen.Mol Cancer Ther 13,1907-1917(2014). 6.T.N.D.Pham et al.,Induction of MNK Kinase-dependent eIF4E Phosphorylation by Inhibitors Targeting BET Proteins Limits Efficacy of BET Inhibitors.Mol Cancer Ther 18,235-244(2019). 7.K.Kumar et al.,BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo.JCI Insight 2,e88032(2017). 8.L.Zeng,M.M.Zhou,Bromodomain:an acetyl-lysine binding domain.FEBS Lett 513,124-128(2002). 9.A.C.Belkina,G.V.Denis,BET domain co-regulators in obesity,inflammation and cancer.Nat Rev Cancer 12,465-477(2012). 10.J.E.Delmore et al.,BET bromodomain inhibition as a therapeutic strategy to target c-Myc.Cell 146,904-917(2011). 11.J.Loven et al.,Selective inhibition of tumor oncogenes by disruption of super-enhancers.Cell 153,320-334(2013). 12.P.Filippakopoulos et al.,Selective inhibition of BET bromodomains.Nature 468,1067-1073(2010). 13.H.Thomas,Therapy:Targeting chromatin remodelling proteins to treat pancreatic cancer.Nat Rev Gastroenterol Hepatol 12,608(2015). 14.J.Shi,C.R.Vakoc,The mechanisms behind the therapeutic activity of BET bromodomain inhibition.Mol Cell 54,728-736(2014). 15.G.Manzotti,A.Ciarrocchi,V.Sancisi,Inhibition of BET Proteins and Histone Deacetylase(HDACs):Crossing Roads in Cancer Therapy.Cancers(Basel)11(2019). 16.C.Dhalluin et al.,Structure and ligand of a histone acetyltransferase bromodomain.Nature 399,491-496(1999). 17.D.A.Santillan et al.,Bromodomain and histone acetyltransferase domain specificities control mixed lineage leukemia phenotype.Cancer Res 66,10032-10039(2006). 18.D.A.Hay et al.,Discovery and optimization of small-molecule ligands for the CBP / p300 bromodomains.J Am Chem Soc 136,9308-9319(2014). 19.V.Garcia-Carpizo et al.,CREBBP / EP300 bromodomains are critical to sustain the GATA1 / MYC regulatory axis in proliferation.Epigenetics Chromatin 11,30(2018). 20.A.R.Conery et al.,Bromodomain inhibition of the transcriptional coactivators CBP / EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma.Elife 5(2016). 21.Y.Yan et al.,The novel BET-CBP / p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.EMBO Mol Med 11,e10659(2019). 22.X.Zhang et al.,Therapeutic targeting of p300 / CBP HAT domain for the treatment of NUT midline carcinoma.Oncogene 39,4770-4779(2020). 23.Y.Li et al.,Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif(BET)Inhibitors Effective in Endocrine-Resistant ER+Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.J Med Chem 63,7186-7210(2020). 24.D.R.Principe et al.,TGFbeta Blockade Augments PD-1 Inhibition to Promote T-Cell-Mediated Regression of Pancreatic Cancer.Mol Cancer Ther 18,613-620(2019). 25.D.R.Principe et al.,Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy.Cancer Res 80,3101-3115(2020). 26.A.Hammitzsch et al.,CBP30,a selective CBP / p300 bromodomain inhibitor,suppresses human Th17 responses.Proc Natl Acad Sci U S A 112,10768-10773(2015). 27.W.A.Cortopassi,K.Kumar,R.S.Paton,Cation-pi interactions in CREBBP bromodomain inhibition:an electrostatic model for small-molecule binding affinity and selectivity.Org Biomol Chem 14,10926-10938(2016). 28.K.Kumar et al.,Cation-pi interactions in protein-ligand binding:theory and data-mining reveal different roles for lysine and arginine.Chem Sci 9,2655-2665(2018). 29.X.Jiang,Y.D.Seo,K.M.Sullivan,V.G.Pillarisetty,Establishment of Slice Cultures as a Tool to Study the Cancer Immune Microenvironment.Methods Mol Biol 1884,283-295(2019). 30.C.Y.Lim et al.,Organotypic slice cultures of pancreatic ductal adenocarcinoma preserve the tumor microenvironment and provide a platform for drug response.Pancreatology 18,913-927(2018). 31.C.B.Westphalen,K.P.Olive,Genetically engineered mouse models of pancreatic cancer.Cancer J 18,502-510(2012). 32.B.T.DeCant,D.R.Principe,C.Guerra,M.Pasca di Magliano,P.J.Grippo,Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models.Front Physiol 5,464(2014). 33.S.R.Hingorani et al.,Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.Cancer Cell 7,469-483(2005). 34.R.L.Siegel,K.D.Miller,A.Jemal,Cancer statistics,2019.CA Cancer J Clin 69,7-34(2019). 35.P.R.Kunk,T.W.Bauer,C.L.Slingluff,O.E.Rahma,From bench to bedside a comprehensive review of pancreatic cancer immunotherapy.J Immunother Cancer 4,14(2016). 36.D.R.Principe,M.Korc,S.D.Kamath,H.G.Munshi,A.Rana,Trials and tribulations of pancreatic cancer immunotherapy.Cancer Lett 504,1-14(2021). 37.F.Xie et al.,The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.Sci Rep 8,8102(2018). 38.A.L.Miller et al.,The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.EBioMedicine 44,419-430(2019). 39.T.Wu,Y.F.Kamikawa,M.E.Donohoe,Brd4’s Bromodomains Mediate Histone H3 Acetylation and Chromatin Remodeling in Pluripotent Cells through P300 and Brg1.Cell reports 25,1756-1771(2018). 40.H.Ono et al.,C646 inhibits G2 / M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer.Scientific Reports 11,10078(2021). 41.L.Buscail,B.Bournet,P.Cordelier,Role of oncogenic KRAS in the diagnosis,prognosis and treatment of pancreatic cancer.Nat Rev Gastroenterol Hepatol 17,153-168(2020). 42.M.P.di Magliano,C.D.Logsdon,Roles for KRAS in pancreatic tumor development and progression.Gastroenterology 144,1220-1229(2013). 43.V.T.Smit et al.,KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas.Nucleic Acids Res 16,7773-7782(1988). 44.C.Almoguera et al.,Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.Cell 53,549-554(1988). 45.M.A.Collins et al.,Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice.J Clin Invest 122,639-653(2012). 46.P.Liu,Y.Wang,X.Li,Targeting the untargetable KRAS in cancer therapy.Acta Pharm Sin B 9,871-879(2019). 47.D.S.Hong et al.,CodeBreak 100:Phase I study of AMG 510,a novel KRASG12C inhibitor,in patients(pts)with advanced solid tumors other than non-small cell lung cancer NSCLC)and colorectal cancer(CRC).Journal of Clinical Oncology 38,3511-3511(2020). 48.T.Shimamura et al.,Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.Clin Cancer Res 19,6183-6192(2013). 49.S.A.Piha-Paul et al.,First-in-Human Study of Mivebresib(ABBV-075),an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins,in Patients with Relapsed / Refractory Solid Tumors.Clin Cancer Res 25,6309-6319(2019). 50.K.Raina et al.,PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.Proc Natl Acad Sci U S A 113,7124-7129(2016). 51.S.Postel-Vinay et al.,First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097:emerging pharmacokinetic / pharmacodynamic elationship and early termination due to unexpected toxicity.Eur J Cancer 109,103-110(2019). 52.P.J.O’Dwyer et al.,Abstract CT014:GSK525762,a selective bromodomain(BRD)and extra terminal protein(BET)inhibitor:results from part 1 of a phase I / II open-abel single-agent study in patients with NUT midline carcinoma(NMC)and other cancers.Cancer Research 76,CT014-CT014(2016). 53.A.J.Stonestrom et al.,Functions of BET proteins in erythroid gene expression.Blood 125,2825-2834(2015). 54.S.A.Piha-Paul et al.,Phase 1 Study of Molibresib(GSK525762),a Bromodomain and Extra-Terminal Domain Protein Inhibitor,in NUT Carcinoma and Other Solid Tumors.JNCI Cancer Spectr 4,pkz093(2020). 55.J.Lewin et al.,Phase Ib Trial With Birabresib,a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins,in Patients With Selected Advanced Solid Tumors.J Clin Oncol 36,3007-3014(2018). 56.S.J.Nicholls et al.,Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial.J Am Coll Cardiol 57,1111-1119(2011). 57.Y.Jiang,Y.Li,B.Zhu,T-cell exhaustion in the tumor microenvironment.Cell Death Dis 6,e1792(2015). 58.F.S.Hodi et al.,Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med 363,711-723(2010). 59.C.Robert et al.,Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.N Engl J Med 364,2517-2526(2011). 60.H.Borghaei et al.,Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.N Engl J Med 373,1627-1639(2015). 61.E.B.Garon et al.,Pembrolizumab for the treatment of non-small-cell lung cancer.N Engl J Med 372,2018-2028(2015). 62.J.Larkin et al.,Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.N Engl J Med 373,23-34(2015). 63.G.T.Gibney,L.M.Weiner,M.B.Atkins,Predictive biomarkers for checkpoint inhibitor-based immunotherapy.Lancet Oncol 17,e542-e551(2016). 64.P.Darvin,S.M.Toor,V.Sasidharan Nair,E.Elkord,Immune checkpoint inhibitors:recent progress and potential biomarkers.Exp Mol Med 50,1-11(2018). 65.R.J.Torphy,Y.Zhu,R.D.Schulick,Immunotherapy for pancreatic cancer:Barriers and breakthroughs.Ann Gastroenterol Surg 2,274-281(2018). 66.J.Zhao et al.,Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer.Nat Commun 10,899(2019). 67.D.R.Principe et al.,TGFbeta Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis.Cancer Res 76,2525-2539(2016). 68.H.Zhu et al.,BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.Cell Rep 16,2829-2837(2016). 69.S.J.Hogg et al.,BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.Cell Rep 18,2162-2174(2017). 70.K.Ebine et al.,Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells.Sci Rep 8,13225(2018). 71.D.O.Adeegbe et al.,BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer.Cancer Immunol Res 6,1234-1245(2018). 72.Y.Pan et al.,Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1.Oncoimmunology 8,e1581529(2019). 73.J.A.Marin-Acevedo,R.M.Chirila,R.S.Dronca,Immune Checkpoint Inhibitor Toxicities.Mayo Clin Proc 94,1321-1329(2019). 74.W.Kabsch,Integration,scaling,space-group assignment and post-refinement.Acta Crystallogr D Biol Crystallogr 66,133-144(2010). 75.A.J.McCoy et al.,Phaser crystallographic software.Journal of applied crystallography 40,658-674(2007). 76.A.Vagin,A.Teplyakov,Molecular replacement with MOLREP.Acta Crystallogr D Biol Crystallogr 66,22-25(2010). 77.E.Potterton,P.Briggs,M.Turkenburg,E.Dodson,A graphical user interface to the CCP4 program suite.Acta Crystallogr D Biol Crystallogr 59,1131-1137(2003). 78.G.N.Murshudov,A.A.Vagin,E.J.Dodson,Refinement of macromolecular structures by the maximum-likelihood method.Acta Crystallogr D Biol Crystallogr 53,240-255(1997). 79.P.Emsley,B.Lohkamp,W.G.Scott,K.Cowtan,Features and development of Coot.Acta Crystallogr D Biol Crystallogr 66,486-501(2010). 80.D.R.Principe et al.,PEDF inhibits pancreatic tumorigenesis by attenuating the fibro-inflammatory reaction.Oncotarget 7,28218-28234(2016). 81.D.R.Principe et al.,Loss of TGFbeta signaling promotes colon cancer progression and tumor-associated inflammation.Oncotarget 8,3826-3839(2017). 82.D.R.Principe et al.,TGFbeta engages MEK / ERK to differentially regulate benign and malignant pancreas cell function.Oncogene 36,4336-4348(2017). 83.R.Winograd et al.,Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.Cancer Immunol Res 3,399-411(2015).

Claims

1. 1. A method of treating cancer associated with a Ras mutation in a subject in need of such treatment, comprising administering to the subject an effective amount of a compound of formula I or a pharma- ceutically acceptable salt thereof; 【Chemistry 1】 During the ceremony, R 12 But, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, propylenyl, -CH 2 (CO)CH=CH 2 , oxiran-2-ylmethyl, or CH 2 (CO)CH 2 Cl, R 11 is a nitrogen-containing bicyclic or tricyclic heteroaryl, aryl, or biaryl, each of which is optionally independently -N(R a ) S (O) 2 R b , -S(O) 2 N.R. a R b , -C(O)NR a R b -N(R a ) C(O)R b -NR a R b , -(C 1 -C 6 Alkylenyl) R c , -(C 1 -C 3 Cycloalkylenyl) R c , aryl, heteroaryl, -(C 1 -C 6 Alkylenyl) R c R c’ , -H, halogen, -CN, propylenyl, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, -OR 70 , -NR 70 R 70 , -C(O)OR 70 , -C(O)NR 70 R 70 , -S(O) 2 R 70 , -S(O) 2 N.R. 70 R 70 , -CH 2 (CO)CH=CH 2 , oxiran-2-ylmethyl, CH 2 (CO)CH 2 Cl, and R 70 and is substituted with one, two or three substituents selected from X is optionally present and, when present, is selected from the group consisting of —O—, —C(O)—, —N(R 77 )- and -CH(R 70 ) - is selected from R 77 -H, halogen, -CN, C 1 -C 3 Haloalkyl, -OR 70 , -NR 70 R 70 , -C(O)OR 70 , -C(O)NR 70 R 70 , -S(O) 2 R 70 , -S(O) 2 N.R. 70 R 70 , and R 70 is selected from the group consisting of R 70 For each occurrence, independently, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, halogen, C 1 -C 6 Haloalkyl, -CN, NO 2 , -OR e , -S(O) 2 N.R. e R f , -C(O)R e , -C(O)NR e R f , -NR e R f -N(R e ) C(O)R f , -(C 1 -C 6 (alkylenyl)-OR e , -(C 1 -C 6 (alkylenyl)-C(O)NR e R f , -(C 1 -C 6 (alkylenyl)-NR e R f , and -(C 1 -C 6 alkylenyl)-N(R e ) C(O)R f is selected from R a and R b For each occurrence, independently, H, C 1 -C 6 Alkenyl, C 1 -C 6 Alkynyl, C 1 -C 6 Haloalkyl, R c , and C 1 -C 6 alkyl, 1 -C 6 The alkyl is optionally -OR e , -NR e R f , -C(O)OR e , -C(O)NR e R f , -S(O)R e , -S(O) 2 N.R. e R f , and R c is substituted with one substituent selected from R c and R c’ is independently selected from aryl, heteroaryl, heterocycle, cycloalkyl, and cycloalkenyl, and each R c The group optionally has 1, 2, 3, 4, or 5 R d is substituted with a group, R d But for each occurrence, independently, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, halogen, C 1 -C 6 Haloalkyl, -CN, -NO 2 , -OR e , -S(O) 2 N.R. e R f , -C(O)R e , -C(O)NR e R f , -NR e R f , -N(R e ) C(O)R f , -(C 1 -C 6 (alkylenyl)-OR e , -(C 1 -C 6 (alkylenyl)-C(O)NR e R f , -(C 1 -C 6 (alkylenyl)-NR e R f , and -(C 1 -C 6 alkylenyl)-N(R e ) C(O)R f is selected from R e and R f For each occurrence, independently, H, C 1 -C 6 Alkyl, C 1 -C 6 Cycloalkyl, aryl, heteroaryl, and C 1 -C 6 haloalkyl.

2. The compound is of formula II, 【Chemistry 2】 During the ceremony, R 1 but, 【Chemistry 3】 and R 2 but, 【Chemistry 4】 and R 3 is H or C 1 -C 6 is alkyl, R 80 But, C 1 -C 3 is alkyl, X 1 , X 2 , and X 3 is independently selected from the group consisting of CH or N.

3. R 12 But, C 1 -C 3 The method of claim 2, wherein the alkyl group is an alkyl group.

4. R 12 The method of claim 2 , wherein is methyl.

5. R 2 but, 【Chemistry 5】 The method according to claim 2, wherein

6. X 1 is N and X 2 is N and X 3 The method of claim 5 , wherein is CH.

7. R 3 But, C 1 -C 3 The method of claim 5 , wherein the alkyl group is an alkyl group.

8. R 3 The method of claim 5 , wherein is methyl.

9. R 1 The method of claim 2 , wherein: 【Chemistry 6】

10. R 80 The method of claim 9 , wherein is ethyl.

11. The compound is of formula III: 【Chemistry 7】 In the formula, R 31 but, 【Chemistry 8】 and R 157 But, Me, CH 2 CH 3 , or CH(CH 3 ) 2 and R 32 But, C 1 -C 6 Alkyl, C 1 -C 6 Alkenyl, C 1 -C 8 Cycloalkyl, -H, -D, C 1 -C 8 selected from the group consisting of substituted cycloalkylenyl, substituted aryl, and substituted heteroaryl; R 33 , R 34 , R 35 , R 36 , R 37 , R 34’ , R 35’ , R 36’ , R 37’ each independently represents -H, halogen, -CN, C 1 -C 3 Haloalkyl, C 1 -C 6 Cycloalkyl, C 1 -C 6 Alkylamines, C 1 -C 6 Cycloalkylamines, C 1 -C 6 Alkyl esters, and C 1 -C 6 2. The method of claim 1, wherein the alkyl amide is selected from the group consisting of alkyl amides.

12. R 33 , R 34 , R 35 , R 36 , R 37 , R 34’ , R 35’ , R 36’ , R 37’ The method of claim 11 , wherein each is hydrogen.

13. R 32 But, C 1 -C 3 The method of claim 11 , wherein the alkyl group is an alkyl group.

14. R 32 The method of claim 11 , wherein is methyl.

15. R 31 but, 【Chemistry 9】 and In the formula, R 157 But, Me, CH 2 CH 3 , or CH(CH 3 ) 2 The method of claim 11, wherein

16. 2. The method of claim 1, wherein the compound is of Formula IV or a pharma- ceutically acceptable salt thereof. 【Chemistry 10】

17. 10. The method of claim 1, further comprising administering to the subject an effective amount of an immune checkpoint inhibitor.

18. 18. The method of claim 17, wherein the immune checkpoint inhibitor comprises a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, or a combination thereof.

19. The method of claim 17, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.

20. 18. The method of claim 17, wherein the immune checkpoint inhibitor comprises nivolumab, pembrolizumab, cemiplimab, atezolizumab, avelumab, durvalumab, or any combination thereof.

21. 18. The method of claim 17, wherein the immune checkpoint inhibitor is administered prior to administration of the compound.

22. 18. The method of claim 17, wherein the immune checkpoint inhibitor is administered subsequent to administration of the compound.

23. 18. The method of claim 17, wherein the immune checkpoint inhibitor is administered simultaneously with administration of the compound.

24. 24. The method of any one of claims 1 to 23, wherein the cancer associated with a Ras mutation is lung cancer, gastrointestinal cancer, breast cancer, pancreatic cancer, colon cancer, or blood cancer.

25. 24. The method of any one of claims 1 to 23, wherein the cancer associated with a Ras mutation is small intestine adenocarcinoma, rectal adenocarcinoma, bile duct carcinoma, gallbladder carcinoma, neuroblastoma, melanoma, or head and neck squamous cell carcinoma.

26. The method of any one of claims 1 to 23, wherein the cancer associated with a Ras mutation is pancreatic ductal adenocarcinoma.

27. 1. A pharmaceutical composition comprising: (a) A compound of formula I, or a pharma- ceutically acceptable salt thereof, 【Chemistry 11】 During the ceremony, R 12 But, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, propylenyl, -CH 2 (CO)CH=CH 2 , oxiran-2-ylmethyl, or CH 2 (CO)CH 2 Cl, R 11 is a nitrogen-containing bicyclic or tricyclic heteroaryl, aryl, or biaryl, each of which is optionally independently -N(R a ) S (O) 2 R b , -S(O) 2 N.R. a R b , -C(O)NR a R b -N(R a ) C(O)R b -NR a R b , -(C 1 -C 6 Alkylenyl) R c , -(C 1 -C 3 Cycloalkylenyl) R c , aryl, heteroaryl, -(C 1 -C 6 Alkylenyl) R c R c’ , -H, halogen, -CN, propylenyl, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, -OR 70 , -NR 70 R 70 , -C(O)OR 70 , -C(O)NR 70 R 70 , -S(O) 2 R 70 , -S(O) 2 N.R. 70 R 70 , -CH 2 (CO)CH=CH 2 , oxiran-2-ylmethyl, CH 2 (CO)CH 2 Cl, and R 70 and is substituted with one, two or three substituents selected from X is optionally present and, when present, is selected from the group consisting of —O—, —C(O)—, —N(R 77 )- and -CH(R 70 ) - is selected from R 77 -H, halogen, -CN, C 1 -C 3 Haloalkyl, -OR 70 , -NR 70 R 70 , -C(O)OR 70 , -C(O)NR 70 R 70 , -S(O) 2 R 70 , -S(O) 2 N.R. 70 R 70 , and R 70 is selected from the group consisting of R 70 For each occurrence, independently, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, halogen, C 1 -C 6 Haloalkyl, -CN, NO 2 , -OR e , -S(O) 2 N.R. e R f , -C(O)R e , -C(O)NR e R f , -NR e R f -N(R e ) C(O)R f , -(C 1 -C 6 (alkylenyl)-OR e , -(C 1 -C 6 (alkylenyl)-C(O)NR e R f , -(C 1 -C 6 (alkylenyl)-NR e R f , and -(C 1 -C 6 alkylenyl)-N(R e ) C(O)R f is selected from R a and R b For each occurrence, independently, H, C 1 -C 6 Alkenyl, C 1 -C 6 Alkynyl, C 1 -C 6 Haloalkyl, R c , and C 1 -C 6 alkyl, 1 -C 6 The alkyl is optionally -OR e , -NR e R f , -C(O)OR e , -C(O)NR e R f , -S(O) 2 R e , -S(O) 2 N.R. e R f , and R c is substituted with one substituent selected from R c and R c’ is independently selected from aryl, heteroaryl, heterocycle, cycloalkyl, and cycloalkenyl, and each R c The group optionally has 1, 2, 3, 4, or 5 R d is substituted with a group, R d But for each occurrence, independently, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, halogen, C 1 -C 6 Haloalkyl, -CN, -NO 2 , -OR e , -S(O) 2 N.R. e R f , -C(O)R e , -C(O)NR e R f , -NR e R f , -N(R e ) C(O)R f , -(C 1 -C 6 (alkylenyl)-OR e , -(C 1 -C 6 (alkylenyl)-C(O)NR e R f , -(C 1 -C 6 (alkylenyl)-NR e R f , and -(C 1 -C 6 alkylenyl)-N(R e ) C(O)R f is selected from R e and R f For each occurrence, independently, H, C 1 -C 6 Alkyl, C 1 -C 6 Cycloalkyl, aryl, heteroaryl, and C 1 -C 6 haloalkyl, or a pharma- ceutically acceptable salt thereof; (b) an immune checkpoint inhibitor; and (c) a pharma- ceutically acceptable carrier.

28. A kit comprising: (a) A compound of formula I, or a pharma- ceutically acceptable salt thereof, 【Chemistry 12】 During the ceremony, R 12 But, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, propylenyl, -CH 2 (CO)CH=CH 2 , oxiran-2-ylmethyl, or CH 2 (CO)CH 2 Cl, R 11 is a nitrogen-containing bicyclic or tricyclic heteroaryl, aryl, or biaryl, each of which is optionally independently -N(R a ) S (O) 2 R b , -S(O) 2 N.R. a R b , -C(O)NR a R b -N(R a ) C(O)R b -NR a R b , -(C 1 -C 6 Alkylenyl) R c , -(C 1 -C 3 Cycloalkylenyl) R c , aryl, heteroaryl, -(C 1 -C 6 Alkylenyl) R c R c’ , -H, halogen, -CN, propylenyl, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, -OR 70 , -NR 70 R 70 , -C(O)OR 70 , -C(O)NR 70 R 70 , -S(O) 2 R 70 , -S(O) 2 N.R. 70 R 70 , -CH 2 (CO)CH=CH 2 , oxiran-2-ylmethyl, CH 2 (CO)CH 2 Cl, and R 70 and is substituted with one, two or three substituents selected from X is optionally present and, when present, is selected from the group consisting of —O—, —C(O)—, —N(R 77 )- and -CH(R 70 ) - is selected from R 77 -H, halogen, -CN, C 1 -C 3 Haloalkyl, -OR 70 , -NR 70 R 70 , -C(O)OR 70 , -C(O)NR 70 R 70 , -S(O) 2 R 70 , -S(O) 2 N.R. 70 R 70 , and R 70 is selected from the group consisting of R 70 For each occurrence, independently, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, halogen, C 1 -C 6 Haloalkyl, -CN, NO 2 , -OR e , -S(O) 2 N.R. e R f , -C(O)R e , -C(O)NR e R f , -NR e R f -N(R e ) C(O)R f , -(C 1 -C 6 (alkylenyl)-OR e , -(C 1 -C 6 (alkylenyl)-C(O)NR e R f , -(C 1 -C 6 (alkylenyl)-NR e R f , and -(C 1 -C 6 alkylenyl)-N(R e ) C(O)R f is selected from R a and R b For each occurrence, independently, H, C 1 -C 6 Alkenyl, C 1 -C 6 Alkynyl, C 1 -C 6 Haloalkyl, R c , and C 1 -C 6 alkyl, 1 -C 6 The alkyl is optionally -OR e , -NR e R f , -C(O)OR e , -C(O)NR e R f , -S(O) 2 R e , -S(O) 2 N.R. e R f , and R c is substituted with one substituent selected from R c and R c’ is independently selected from aryl, heteroaryl, heterocycle, cycloalkyl, and cycloalkenyl, and each R c The group optionally has 1, 2, 3, 4, or 5 R d is substituted with a group, R d But for each occurrence, independently, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, halogen, C 1 -C 6 Haloalkyl, -CN, -NO 2 , -OR e , -S(O) 2 N.R. e R f , -C(O)R e , -C(O)NR e R f , -NR e R f , -N(R e ) C(O)R f , -(C 1 -C 6 (alkylenyl)-OR e , -(C 1 -C 6 (alkylenyl)-C(O)NR e R f , -(C 1 -C 6 (alkylenyl)-NR e R f , and -(C 1 -C 6 alkylenyl)-N(R e ) C(O)R f is selected from R e and R f For each occurrence, independently, H, C 1 -C 6 Alkyl, C 1 -C 6 Cycloalkyl, aryl, heteroaryl, and C 1 -C 6 haloalkyl, or a pharma- ceutically acceptable salt thereof; (b) an immune checkpoint inhibitor; and (c) the compound and instructions for administering the immune checkpoint inhibitor.